POROUS NANOMATERIALS AS CONTROLLED DRUG DELIVERY SYSTEMS by Gordon, Jeffrey Kenneth
Western University 
Scholarship@Western 
Digitized Theses Digitized Special Collections 
2011 
POROUS NANOMATERIALS AS CONTROLLED DRUG DELIVERY 
SYSTEMS 
Jeffrey Kenneth Gordon 
Follow this and additional works at: https://ir.lib.uwo.ca/digitizedtheses 
Recommended Citation 
Gordon, Jeffrey Kenneth, "POROUS NANOMATERIALS AS CONTROLLED DRUG DELIVERY SYSTEMS" 
(2011). Digitized Theses. 3473. 
https://ir.lib.uwo.ca/digitizedtheses/3473 
This Thesis is brought to you for free and open access by the Digitized Special Collections at 
Scholarship@Western. It has been accepted for inclusion in Digitized Theses by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
POROUS NANOMATERIALS AS CONTROLLED DRUG
DELIVERY SYSTEMS
(Spine Title: Porous nanomaterials as controlled drug delivery systems)
(Thesis Format: Integrated Article)
By:
Jeffrey Kenneth Gordon
Graduate program in Engineering Science 
Department of Chemical and Biochemical Engineering
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Master of Engineering Science
School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada
© Jeffrey Kenneth Gordon 2011
Abstract
MIL-53(Fe) was synthesized by conventional electric (CE) heating, and by ultrasound 
(UTS) and microwave (MW) irradiation to develop rapid and energy efficient synthesis 
techniques. MW and UTS conditions rapidly produced small and highly crystalline 
materials in 10 and 7 minutes, respectively. The energy consumption of UTS and MW 
irradiation were less than CE heating, confirming that these two technologies are quicker, 
more efficient and greener alternatives to conventional synthesis methods. The use of 
MIL-53(Fe), MIL-101, and SBA-15 as matrices for the adsorption and in vitro drug 
delivery of acetaminophen, progesterone, and stavudine was studied. An initial burst 
release from both MIL-53(Fe) and MIL-101 was followed by a slow diffusion-controlled 
release, which occurred for up to 6 and 5 days, respectively. Complete release from 
SBA-15 occured in as quickly as 30 minutes as a result of rapid drug dissolution and 
diffusion out of the pores.
Keywords: metal-organic frameworks, microwave irradiation, ultrasound,
crystallization, rapid synthesis, silica-based ordered mesoporous material, 
incipient wetness, drug delivery, MIL-53(Fe), MIL-101, SBA-15
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In the 1990s there was a significant increase in the number of new drugs having larger 
molecular sizes, higher dose sensitivities, and poorer stabilities in biological 
environments.1 The difficulties associated with conventional drug administration has 
resulted in a push towards the development of efficient encapsulation and controlled- 
release technologies, capable of improving clinical efficacy and patient compliance, 
decreasing the frequency and cost of administering drugs, and extending product life. 
Drug delivery now represents one of the fastest growing segments in the pharmaceutical 
industry, with approximately 10% annual growth.1
Drug delivery is achieved by encapsulating pharmaceuticals within a porous compound. 
Three types of porous materials exist, including organic, inorganic, and coordination 
polymers.2 Extensive research has been dedicated towards using various types of organic 
nanoparticles as drug delivery systems (DDSs). Although these systems have several 
advantages and represent the majority of DDSs now approved for use by the Food and 
Drug Administration (FDA), several limitations affect their applicability as DDSs. 
Liposomes and micelles suffer from poor stability that limits both their route of 
administration and shelf life. It is also very difficult to develop micelles and liposomes 
that release therapeutic agents in a controlled and sustained manner. The degradation by­
products of synthetic polymers pose toxicity problems, and the lack of control over 
monomer purity for natural polymers, such as chitosan, leads to a lack of reproducibility 
in their release profiles. Dendrimers suffer from low blood stability, and are quickly 
eliminated from the body by the kidneys and liver.1
3
These limitations have led researchers to search for alternative systems with longer half- 
lives and higher therapeutic efficacies. Recent research on metal-organic framework 
(MOF) materials and inorganic silica-based ordered mesoporous materials (SMMs) has 
revealed that these two classes of materials are very promising in the field of drug 
delivery. Their high porosities and surface areas have afforded these materials 
applications not only in the field of controlled drug delivery, but in many other areas of 
potential economic and environmental importance as well.
1.2. Porous Solids
In this study, two MOF materials and an SMM were synthesized, characterized, and 
investigated as DDSs. The two MOF materials that were studied are MIL-53(Fe) and 
MIL-101 (MIL = Materials of Institute Lavoisier). MIL-53(Fe) is a microporous iron(III) 
benzenedicarboxylate MOF, which was selected because of its flexible structure. It is 
capable of opening and closing its pores to maximize host-guest molecule interactions, 
thus prolonging drug delivery. MIL-53 has the formula Min(0H)*(02C-C6H4-C02)*H20 
(M = Al3+, Cr3+ or Fe3+).5 MIL-101 was selected because of its high drug loadings. MIL- 
101 is a rigid chromium benzenedicarboxylate MOF, possessing large mesoporous cages 
(~29 and 34 A). MIL-101 has the formula Cr30X(H20)2[(02C)-C6H4-(C02)]3-«H20  
(where X = F,OH and n is ~25).6 The SMM that was selected in this study is SBA-15 
(SBA = Santa Barbara Amorphous). It has a hexagonally-ordered array of tunable pores 
which can range in diameter from 5 to 30 nm. It has a high surface area, a large pore
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volume, and a silanol-containing surface capable of being functionalized, thus enabling 
high drug loadings and release profiles which can be highly modified.7
1.3. Model Drugs
The drug release from each of these materials was investigated using three drug 
molecules: stavudine, acetaminophen, and progesterone. These molecules were selected 
because of their different physicochemical properties. Stavudine is a nucleoside reverse 
transcriptase inhibitor (NRTI) used for the treatment of human immunodeficiency virus 
(HIV) (Figure 1-1). It was approved for use by the FDA in 1994. Ever since acquired 
immunodeficiency syndrome (AIDS) was discovered in 1981, it has remained one of the 
greatest public health challenges. Every year more than 2.5 million people become 
infected with human immunodeficiency virus (HIV), resulting in the number of people 
living with this virus continuing to grow. Seven NRTIs have been approved for use, but 
in general they have limited stabilities and poor bioavailabilities. The bioavailability of 
an orally administered drug can be affected by incomplete absorption and first-pass 
metabolism. As an NRTI, stavudine has a reasonably high bioavailability of about 80%. 
However, its half-life in systemic circulation is about 1 to 1.6 hours, necessitating 
frequent doses which results in severe dose-dependent side effects.8 For this reason, 





Figure 1-1. Molecular structure of stavudine.
Acetaminophen (also known as paracetamol) is an analgesic which distributes rapidly and
evenly throughout most tissues (Figure 1-2). Like stavudine, it is orally administered, and 
has a bioavailability ranging from 70 to 90% and a short plasma half-life ranging from 1.9 
to 2.5 hours.9
Progesterone is a steroid hormone belonging to the progestogen class that naturally occurs 
in both males and females (Figure 1-3). It is administered to individuals with a long-term 
decline of natural levels in the body, as well as to patients with acute situations. Like all 
steroid hormones it is hydrophobic, therefore, when taken orally it has a poor 
bioavailability and a half-life upwards of 50 hours.10
H
Figure 1-2. Molecular structure of acetaminophen.
6
Figure 1-3. Molecular structure of progesterone.
1.4. Thesis Objectives
This thesis in general aims to investigate the drug release profiles of three important 
porous solids: MIL-53(Fe), MIL-101, and SBA-15. The objective will be to optimize the 
drug incorporation into each of these materials and obtain controlled, sustained release of 
stavudine, acetaminophen, and progesterone. The release profiles of each of the 
materials, as well as each of the drugs will be compared. MIL-53(Fe) will also be 
synthesized by three different methods, and the operating conditions of each method will 
be varied in an attempt to optimize the reaction conditions to produce small and 
homogeneous crystals while minimizing energy consumption.
1.5. References
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Since liposomes were first described in the 1960s and proposed as carriers of drugs and 
proteins for treating disease, there has been a significant development in the utilization of 
drug carriers for delivery.1 So far, over two dozen nanotechnology-based therapeutic 
products have been approved by the FDA for clinical use, and more are currently in 
clinical trials. The pursuit of drug delivery systems (DDSs) can be justified by their 
ability to improve the therapeutic and pharmacological properties of conventional free 
drugs.2 These systems are designed to alter the pharmacokinetics and biodistribution of 
drugs, and/or to function as sustained release systems. The ultimate goal is to improve 
the therapeutic effect of the entrapped drug by enhancing its delivery to, or uptake by, 
target cells and/or reducing the toxicity of the drug to healthy tissue.3 Problems exhibited 
by free drugs that can be improved by these systems include (1) poor solubility, (2) tissue 
damage on extravasation, (3) rapid breakdown of the drug (4) rapid drug clearance, and 
(5) lack of selectivity for target tissues.2 The first problem is explained by the inherent 
difficulty of achieving convenient pharmaceutical formats. Hydrophobic drugs suffer 
from poor dissolution in aqueous media, and the use of solubilizers as excipients are 
associated with side effects. Certain DDSs such as lipid micelles, liposomes, and MOFs 
provide both hydrophobic and hydrophilic environments, enhancing solubility. Just as 
importantly, drug levels are continuously maintained in a therapeutically desirable range, 
reducing adverse side effects. The second problem - tissue damage caused by inadvertent 
extravasation of cytotoxic drugs - can be reduced or eliminated by regulated drug release 
from the DDS. The third and fourth problems of conventional therapy require that higher
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doses be administered, which may cause side effects if the drug suffers from a lack of 
selectivity for the target tissue. DDSs protect drugs from premature degradation under 
physiological pH, thus, lowering the required dose. DDSs can also substantially alter the 
pharmacokinetics of drugs and reduce clearance by the kidneys, especially for small 
molecules. By decreasing the number of required dosages and possibly implementing 
less invasive dosing, patient compliance becomes improved resulting in a higher 
therapeutic effect. Finally, the distribution of drugs not only to diseased tissue but also to 
normal tissues leads to side effects that reduce the amount of drug that can be 
administered. However, limiting the dosage to prevent side effects also results in lower 
concentrations in target tissues, lowering the therapeutic effect. By site-specific targeting, 
DDSs can increase drug concentrations in diseased tissues, improving drug specificity 
and decreasing harmful side effects.2
2.1.2. Particle Size and Cellular Uptake
Nanomaterials have been used for a number of applications, including catalysis, gas 
adsorption/separation/storage, electronics, lithographic techniques, materials engineering, 
and biomedicine. Their applications in the field of biomedicine include drug delivery, 
gene delivery, cancer therapy, and as biosensors.4 Their attractiveness for biomedicine is 
based on their unique properties, including large specific surface areas, crystallinity, 
surface chemistry, quantum properties, ability to adsorb and carry other compounds, and 
size.3 Particle size is an extremely important factor controlling the performance and 
function of DDSs. Smaller particles have increased dissolution rates due to their greater
11
surface area-to-volume ratios, enabling them to overcome solubility-limited 
bioavailability. They also have a greater cellular uptake, reducing the risk of being 
rapidly cleared from the body by the liver or spleen and minimizing their uptake by the 
reticuloendothelial system (RES). In fact, 100 nm size particles exhibit 15-250-fold 
greater uptake efficiencies than small microparticles (1-10 pm). The bioavailability and 
blood circulation time are also strongly dependent on size. Particles with diameters less 
than 10 nm are rapidly cleared from the body through extravasation of capillary 
fenestrations and by the kidneys;5 particles with diameters ranging from 10 to 70 nm are 
able to enter into very small capillaries;6 particles with diameters ranging from 70 to 200 
nm have the longest circulation times;7 and particles with diameters greater than 200 nm 
are typically sequestered by the spleen, resulting in eventual removal by phagocytes.8
However, many challenges must be overcome if the application of nanotechnology in the 
field of drug delivery is to result in improved therapies. A critically important process for 
nanoparticles to become effective in their therapeutic functions is that they can easily 
enter target cells. Yet, this inherent requirement is also a cause of major concern that may 
lead to potential toxic effects. Compared to traditional medicines, nanoparticles easily 
enter cells, however this could produce adverse effects due to the small size, large surface 
area, and/or high reactivity o f some nanoparticles.4 Biodegradable and biocompatible 
DDSs are needed to ensure that (1) the drug is released when the formulation enters the 
cell, and (2) the nanoparticle degradation products are not toxic to the cell. The Royal 
Society and Royal Academy of Engineering 2004, has proposed that only particles with 
sizes < 100 nm can be defined as nanoparticles.3 Nanoparticles this small can readily 
translocate among different cells, tissues, and organs, potentially posing a great risk to
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human health.4 Thus, a fundamental understanding of the mechanisms governing cellular 
uptake is an important step towards understanding the biological fate of nanoparticles.
Cell membranes are somewhat permeable, allowing only small molecules to pass through 
into the cell. Oxygen, carbon dioxide, water, and small hydrophobic or nonpolar 
molecules are driven by their concentration gradients to freely diffuse through the 
membrane. Ions and amino acids are actively transported across the membrane by 
integral membrane protein pumps or ion channels.4 DDSs, on the other hand, must be 
shuttled across the cell membrane by a process called endocytosis. Typically, larger 
DDSs will remain outside cells where they release their payloads to create high 
extracellular drug concentrations, while smaller systems will be endocytosed directly. In 
this process the cell internalizes objects by enclosing a portion of the plasma membrane 
around the object, which pinches off from the rest of the membrane to form a vesicle. 
Subsequent to their uptake, DDSs are transported from early endosomes to sorting 
endosomes where they are either exported from the cell or transported to secondary 
endosomes/lysosomes. From here the DDSs will have one of two fates: either they are 
degraded and the activity o f the encapsulated drug is diminished, or they escape into the 
cytoplasm and release their payloads to produce their desired therapeutic effect.9
Several different endocytotic processes exist, including phagocytosis, pinocytosis, 
receptor-mediated endocytsis, and caveolae-dependent or clathrin-mediated endocytosis 
(Figure 2-1). Particles with diameters >750 nm are internalized by phagocytosis, a 
process mainly conducted by specialized cells such as monocytes, macrophages, and 
neutrophils. Almost all cell types can perform pinocytosis or macropinocytosis to 
internalize particles ranging from a few to several hundred nanometers in diameter. In
13
clathrin-mediated endocytosis the particles are deposited in small vesicles (usually <100 
nm in diameter) which eventually fuse with early endosomes in the cytosol. The most 
important cellular uptake process for nanoparticles by endothelial cells is caveolae- 
mediated endocytosis, in which vesicles 50 to 80 nm in size are formed.4 Each type of 
nanoparticle has a preferred type o f entry into the cell, which is dependent on such factors 
as size, shape, surface charge and functionalization. For example, Edetsberger at al.10 
showed that nanoparticles about 20 nm in diameter were sufficiently small that 
endocytosis did not contribute to cellular uptake. In another study, poly(DL-lactide-co- 
glycolide)acid (PLGA) nanoparticles were ingested by endocytosis and released into the 
cytosol intact, resulting in cytoplasmic delivery of the encapsulated drug.11,12 The escape 
from the endosomes was attributed to a change in surface charge of the PLGA 
nanoparticles from negative to positive. This hypothesis was supported by data obtained 
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Figure 2-1. Schematic of the known pathways for intracellular uptake of 
nanoparticles.4
2.1.3. Passive/Active Targeting
In the domain of drug delivery, DDSs can be designed to either passively or actively 
target the diseased site. Passive targeting relies on the extravasation of the particles into 
the diseased tissue by the enhanced permeability and retention (EPR) effect. The escape 
of DDSs from blood circulation is restricted to sites where the capillaries have open 
fenestrations.13 In certain pathological conditions the endothelial barrier may become 
perturbed, increasing the permeability of the tissue vasculature and allowing DDSs 
(which are normally excluded) to extravásate and accumulate in the tissue interstitial 
space. In particular, DDSs can enter into tumour tissues and localize there by the EPR 
effect as a result of leaky blood vessels, which may form gaps as large as 600 to 800 nm 
between adjacent endothelial cells. This common feature of tumours is a result of 
angiogenesis, which is a process involving the reemitment of new blood vessels to the
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tumour to meet its growing demands of oxygen and nutrients. Tumours also have 
impaired lymphatic drainage, so the accumulated DDSs are retained (Figure 2-2).2
Figure 2-2. Schematic representation of different mechanisms by which 
nanocarriers can deliver drugs to tumours. Polymeric nanoparticles are shown as 
representative nanocarriers (circles).14
DDSs relying on the EPR effect require long half-lives for optimal accumulation of the 
drug in the diseased tissue. Once the DDS has accumulated then the drug must be 
released at a rate that maintains the concentration within the therapeutic range for 
sufficient periods of time. In tumours, for example, the drug concentration should be 
maintained within the therapeutic range for a period of at least several hours.2 Although
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passive targeting is the conventional therapeutic approach for treating disease, it suffers 
from several limitations. Especially in the case of chemotherapy, the lack of control of 
this process may induce multiple-drug resistance (MDR) whereby cancer cells become 
resistant to one or more drugs. Furthermore, the EPR effect may not be exhibited by all 
tumours, and the permeability of vessels may vary significantly throughout a single 
tumour, limiting the ability of DDSs to extravásate into the tissue.14
Active targeting can overcome these limitations. As the name suggests, this process is 
characterized by the ability of DDSs to actively target specific cells rather than tissues. 
This is accomplished by functionalizing the surface with biomolecules through various 
techniques, including physical adsorption, electrostatic binding, complementary 
recognition and covalent coupling.9 The idea of this technique is to attach ligand 
molecules which have a high affinity and selectivity to receptor molecules that are 
uniquely expressed on the target cell surface. Ideally the receptors on the surface of the 
target cells should be overexpressed relative to normal cells to maximize specificity.14 
The nanoparticles can either release their contents in close proximity to the target cells, 
attach to the membrane of the cell through ligand-receptor interactions and act as an 
extracellular sustained-release drug depot, or internalize into the cell by receptor- 
mediated endocytosis (RME) (Figure 2-2 inset).14
Internalization leads to higher intracellular drug concentrations and increased therapeutic 
activity. DDSs can even be modified to target specific organelles within the cell. For 
example, anionic particles will usually remain in lysosomes, while cationic particles will 
concentrate in the cytoplasm and within mitochondria.9 There are many different types of 
molecules that can be used as targeting ligands, including antibodies, aptamers, growth
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factors or vitamins, and peptides. Cancer cells are most commonly targeted by growth 
factor or vitamin interactions, since they overexpress receptors for nutrition to maintain 
their fast-growing metabolism. An example of receptors which are overexpressed on the 
surface of some cancer cells which have been used for targeting include the epidermal 
growth factor (EGF) receptor, the folate receptor (FR), and the transferrin receptor (TfR). 
Functionalization of DDS surfaces with EGF, folate, and Tf has improved intracellular 
delivery of encapsulated drugs and therapeutic outcome in animal models.14
2.2. Metal-Organic Frameworks
2.2.1. Background
Since this class of porous solids emerged as a new domain of research in the early 1990s, 
remarkable advancements have been made in their chemistries. Before becoming known 
as MOFs they were more generally referred to as coordination polymers. This term 
correctly identifies that these materials contain small clusters of inorganic polyhedra 
which are connected together by ligand monomers through coordination bonds, however 
it is a somewhat simplistic definition that does not consider the final structure or 
morphology o f the materials. The discovery that these hybrid solids contain a large 
dimensionality, forming either chains (ID), layers (2D) or frameworks (3D) led to their 
classification as MOFs.15 This classification defines them as materials with strong 
bonding and a high degree o f robustness, linking units that are available for modification, 
and geometrically well-defined structures.16
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In general, the porosity of every type of porous structure belongs to one of the following 
four categories: OD cavities, ID channels, 2D layers, or 3D intersecting channels (Figure 
2-3). OD cavities (dots) are completely enclosed by surrounding wall molecules, 
preventing entrapped guest molecules from escaping. MOFs can be designed to have 
channels, layers, or intersecting channels, each o f which can accommodate and exchange 
guest molecules. 17
a) Dots (OD cavity) b) Channels (ID  space)
c) Layers (2D space) d) Intersecting channels (3D space)
Figure 2-3. Classes of porous structures based on spatial dimensions.17
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This chemical versatility that MOFs provide is the sole reason why they continue to 
receive so much interest from various domains in the scientific community, including 
physics, chemistry and materials science. Before they were discovered, there existed two 
types of porous materials -  organic and inorganic materials. MOFs combine both organic 
and inorganic groups within their structures, thus they represent a new type of porous 
material referred to as hybrid solids. The two largest subclasses of inorganic solids are 
the aluminophosphates and aluminosilicates. Zeolites are members of the aluminosilicate 
subclass, whose structures are composed o f interconnected tunnels or cages within which 
water molecules or metal ions are inserted. Their porosity is provided by the elimination 
of these species from the pores. The aluminophosphates are composed of tetrahedral Al3+ 
and P5+ ions linked by comer-sharing oxygen atoms. 17 Structurally, MOFs are very 
similar to inorganic porous solids in that both of their three-dimensional skeletons are 
composed o f secondary building units (SBUs). In place of the inorganic tetrahedral 
species found in the structure of inorganic porous solids, though, MOFs contain organic 
linker molecules. The properties of MOFs also resemble those of zeolites, such as the 
adsorption o f gases and shape-selective catalysis of both materials. However, MOFs 
offer a much wider range of structures and properties such as high porosity, pore 
dimensionality, and functionality of metal ions and organic linkers. 18
The MOF structure contains two central components -  inorganic metal centers and 
organic linkers. The two characteristics o f the metal centers and linkers which are 
important for defining the final structure of the framework are the number and orientation 
of their binding sites (coordination numbers and coordination geometries). MOFs can be 
constructed from a great variety of transition metal ions, with coordination numbers
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ranging from two to seven. Many different coordination geometries may be formed as a 
result of this large selection of metals, including linear, T- or Y-shaped, tetrahedral, 
square-planar, square-pyramidal, trigonal-bipyramidal, octahedral, trigonal-prismatic, and 
pentagonal-bipyramidal. 17 Furthermore, considering the large number of organic linkers 
which can be associated with the metals and the different possible linkages, binding 
strength and directionality, the number of possible combinations is seemingly infinite. 
Consequently, many different MOF framework topologies exist, forming either 
microporous (pore diameter <2 nm) or mesoporous (pore diameter between 2-50 nm) 
channels. The existence of organic and inorganic species in the MOF structure also 
presents an opportunity to incorporate both hydrophilic and hydrophobic parts within the 
pores, thus allowing for control over the adsorption properties. 15
Owing to the infinite number of possible combinations between inorganic and organic 
parts, soon after the discovery of MOFs a rationalization became necessary for organizing 
the structures into classes. The inorganic clusters that are linked to the organic 
component were observed to resemble the shapes of simple geometric figures (diamonds, 
sodalites, etc.). These became known as secondary building units (SBUs) which, by 
sharing of vertices through the organic linkers, build up the final solid. 15 The majority of 
MOFs, including the MIL family (MIL = Materials of Institute Lavoisier), incorporate a 
carboxylate functionality to chelate the metal ions and lock them into rigid metal-oxygen- 
carbon clusters. The first carboxylate MOFs designed to resemble this structure were 
MOF-2 and MOF-5. The MOF-5 structure is composed of octahedral SBUs, each of 
which is formed by four Zn0 4  tetrahedra. These SBUs are joined together by benzene
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dicarboxylate linkers to give an extended 3D cubic framework (Figure 2-4) with an 
exceptionally high porosity and stability. 19
Figure 2-5 shows some of the SBUs that are formed in carboxylate MOFs. The inorganic 
units are defined by metal-oxygen polyhedra (such as the ZnC>4 tetrahedra in MOF-5). 
The carboxylate atoms that are bound to these polyhedra define the vertices of the SBUs, 
which are held together by the organic linkers (such as the benzene dicarboxylate linkers 
in MOF-5) . 19
Porous coordination compounds in general can be further classified into three categories, 
called generations. First generation compounds have a microporous framework held 
together only by guest molecules, and which collapse irreversibly upon guest removal. 
Second generation compounds have stable and robust porous frameworks which exhibit 
permanent porosity when guest molecules are evacuated from the pores. Third generation
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compounds have flexible frameworks which respond to external stimuli (light, 
temperature, pressure, electric or magnetic field, guest molecules, etc.) and change their 
structures reversibly. The stimulus can induce either an expansion or a contraction of the 
cell volume and induce movements larger than 1 0  A. Most inorganic porous solids fall 
under the category of second generation compounds. MOFs on the other hand, can be 
rigid and robust second generation compounds as well as highly flexible and dynamic 
third generation compounds.17
Inorganic units SBUs
Figure 2-5. Examples of SBUs from carboxylate MOFs.19
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2.2.2. Synthetic Approaches
Successful synthesis of an MOF requires the reaction of a bridging ligand with a metal 
ion having more than one vacant or labile site . 20 Syntheses are typically carried out under 
solvothermal conditions (> 100°C) from a mixture containing the ligand and metal salt for 
12-48 h .21 Most commonly used solvents include water, alcohols, dialkyl formamides, 
and pyridine . 15 Some of the more labile metal ions which are most often used include 
Cu+, Cu2+, Ag+, Cd2+, Zn2+, Co2+ and Ni2+. However, one of the difficulties in using 
labile metal ions is that they do not have a strong preference for a given geometry, 
leading to a lack of control and predictability over the structure of the network obtained. 
Flexibility in a bridging ligand having a number of possible conformations can also 
contribute to this problem. Another difficulty is that a single metal coordination 
geometry can propagate into more than one type of framework topology. 20 For example, 
more than 1 0 0  different topologies are possible for linking tetrahedral building blocks 
together. 19 O f course, during synthesis there are other important structure-determining 
factors affecting product crystallinity and yield, including the pH, concentration, solvent 
polarity, and temperature. It has been shown that only subtle changes in these parameters 
can lead to significant changes in product crystallinity and yields, or the formation of 
entirely new phases. 16 Therefore, a careful selection of reaction conditions is important. 
Temperature is an especially important factor. Under solvothermal conditions the 
dielectric properties of the solution change, leading to weakened intermolecular 
interactions between the solvent molecules. For example, at 180°C the pH of water 
becomes 5.5, thus, an extrapolation of the conditions applied at room temperature is not 
valid since the chemistry o f the solution is not the same at elevated temperatures. An
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excellent example of the temperature influence was demonstrated by the synthesis of 
cobalt(II) succinates between room temperature and 250°C. Over this temperature range 
seven different materials were synthesized. As the temperature increased the number of 
coordinated water molecules per cobalt atom decreased (when T < 100°C), the edge­
sharing connectivity for the Co2+ octahedra increased, the coordination numbers for 
carboxylate groups increased, and above 100°C hydroxide groups were incorporated into 
the phases. The dimensionality of the structures was also changed. One-dimensional 
structures were isolated at 60°C (with isolated octahedral for the inorganic part) and at 
100°C (with isolated inorganic trimers). The framework became two-dimensional at 
150°C in which 14-membered rings of comer-sharing Co octahedra were obtained. The 
frameworks were three-dimensional above 190°C and 250°C and the inorganic 
subnetwork was always 2D, but the connectivity of the M-O-M bonds was higher at the 
higher temperature. 15
The nature of the metallic salt also greatly influences the nature of the final products. 
Owing to their own redox characteristics, counter ions of metal salts can influence the 
reaction conditions. The Zn /1,4-benzenedicarboxylic acid/solvent reaction system 
resulted in the synthesis o f MOF-5 with NO3', CH3CO2", and O2" as the counter ion of the 
salt, however, when SOT was used an unknown phase was synthesized.22 
Recently, significant steps have been taken in developing more efficient methods of MOF 
synthesis. The conventional solvothermal method can yield high quality crystals, but it 
suffers from long reaction times and can be difficult to scale above ~1 g. There is a huge 
potential for industrial applications of MOFs, therefore researchers have been 
investigating new and efficient alternative synthesis techniques capable of reducing
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production costs by decreasing reaction times and improving energy efficiency. These 
techniques include electrochemical methods, microwave, sonochemical, and solvent-free 
mechanochemical syntheses.21
Microwave heating is a method that has already been applied to inorganic porous 
compounds as a means of accelerating their reaction rates. Crystallization of these 
materials using conventional solvothermal synthesis methods usually requires several 
days as a result of slow heat transfer. Microwave heating has proven to be a much more 
efficient synthesis technique, resulting in rapid crystallization, homogeneous nucléation, 
vast reductions in particle size/size distribution, higher yields, and allowing for facile 
morphology control and efficient evaluation of process variables. 23 The rate 
enhancements under microwave irradiation are thought to be a consequence of the intense 
localized heating that can rapidly be attained in the microwave field. This is referred to 
as the thermal/kinetic effect, but “specific microwave effects” are also responsible for the 
accelerations which cannot be achieved by conventional heating. There have also been 
suggestions of the existence of “non-thermal microwave effects” which result from a 
direct interaction of the electric field with dipolar molecules in the reaction medium . 24
Of the few studies that have investigated microwave heating for MOF synthesis, the 
results appear to be very promising. Conventional synthesis methods of MIL-100 and 
MIL-101 require heating for 96 h at 220°C. However, Chang and co-workers25 have 
shown that under microwave irradiation these MOFs can be formed in less than 1 h. 
Another study demonstrated the accelerated reactions of a cubic nickel glutarate, MIL-77, 
which previously required several hours or days depending on the reaction temperature. 
Microwave irradiation produced the more stable tetragonal nickel glutarate within a few
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minutes.26 Recently, our group demonstrated a novel hybrid synthesis technique 
involving initial UTS irradiation followed by MW irradiation for rapid synthesis of 
IRMOF-1. Compared with IRMOF-1 synthesized by means of CE heating, crystallites 
synthesized using this approach were more cubic shaped, much smaller (size reduction by 
a magnitude of approximately 10), had a narrower particle size distribution (5-15 pm), 
and had similar high surface areas (-2470 m2/g) . 27 Finally, Morris et al. 28 have reported 
the synthesis of an anionic MOF by conventional and microwave conditions using an 
ionic liquid l-ethyl-3-methylimidazolium bromide, as the solvent and template. Their 
results indicate that microwave irradiation produces MOFs that are purer in phase and 
have a higher crystallinity.
Another method that accelerates reactions and produces small and homogeneous crystals 
is sonochemical synthesis. There have only been a few investigations using this method, 
but the results are promising. The accelerated reactions under ultrasound conditions are a 
result of a phenomenon termed “acoustic cavitation”. This process involves the 
formation, growth, and implosive collapse o f cavitation bubbles generated in the liquid by 
the ultrasound wave. Extremely high local temperatures (> 5000 K), pressure (> 2000 
atm), and heating and cooling rates (> 1011 K/s) are generated as a result.23 MOF-177 and 
a Zn-2,2’-bipyridine-5,5’-dicarboxylate MOF synthesized by ultrasonic irradiation 
produced crystals very similar to those obtained from conventional heating and 
microwave irradiation. In the case of MOF-177, crystals had superior properties to those 
synthesized by microwave irradiation.21 Furthermore, synthesis of Zn3(BTC)2- I 2 H2O by 
this method allowed for a control of the crystal size from 50-900 nm depending on the
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reaction time .29 Despite these results the beneficial effects of MOF sonochemical 
synthesis have yet to be fully explored.
2.2.3. Applications
For a long time inorganic porous solids have had applications in petrochemistry, catalysis 
and selective separation as a result of their porosity, high thermal stability and surface 
area. However, up until the discovery of mesoporous materials, an important limitation 
o f these materials was the relatively small size of the pores. MOFs provided a 
breakthrough, since they have potentially unlimited porosities and surface areas, 
including all the desired properties of inorganic solids. Currently, we are living in a time 
when energy problems must be addressed by the development of sustainable and 
“greener” alternatives to existing technologies. Owing to the tunability of their structures 
and the increasingly efficient and greener synthesis techniques, MOFs can have many 
applications in these areas. MOFs have electronic, optical and magnetic applications, as 
well as applications in the areas of catalysis, gas adsorption/separation/storage, and drug 
adsorption/ delivery. 15
In the field of catalysis, the advantage of MOF catalysts over other nanoporous materials 
like zeolites and activated carbon stem from their inorganic-organic hybrid nature and the 
tunability of their structures. Not only may the organic linker provide catalytic sites in 
addition to the metal catalytic sites, but it may also be used as a scaffold to bind catalytic 
complexes. The synthetic flexibility of MOFs allows for a greater control of the pore size 
and environment, allowing for a higher selectivity.21 MOF catalysis mainly includes
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cyanosilylation, the Diels-Alder reaction, hydrogenation, esterification, and CO 
oxidation, however, many others exist. 15 MOFs have also been used as templates for 
nanoparticles in the area of guest-based catalysis. Much of this work has focussed on 
MOF-5, which has been encapsulated with Pd, Cu, Ru, Cu, ZnO, and Au nanoparticles by 
various methods to catalyze such reactions as cyclooctene hydrogenation, methanol 
production from synthesis gas and the oxidation of 1-phenylethanol. 21 Based on previous 
results from inorganic mesoporous materials, the surface functionalization of MOF pores 
should also be a promising research area for catalytic applications, however, this area has 
yet to be explored.
The domain of gas adsorption/separation/storage has become increasingly important as 
worldwide fossil fuel reserves continue to decrease. MOFs may provide a solution to this 
problem for their capacity to adsorb high amounts of important gases like CO2, H2, O2, 
CH4, CO, and NOx in their pores. The ease of evacuating solvents from the pores of 
MOFs, coupled with their high surface areas and tunable pore sizes makes them 
particularly attractive in this field. So far, the use of MOFs in the separation of mixtures 
of gases has been confined primarily to capturing H2, CH4 and CO2 .15 However, progress 
has also been made in the removal of other toxic and environmentally hazardous gases as 
well. Weireld and coworkers30 investigated the hydrogen sulphide (H2S) adsorption 
properties of several MOFs. H2S is known to be a very challenging adsorbate due to the 
adsorbent decomposition and difficult regeneration that usually occur upon uptake. 
However, this group observed both that MIL-47(V) and MIL-53(A1, Cr) display little 
degradation and reversible uptake, and that MIL-53 materials displayed step-wise 
adsorption, making them attractive materials for the purification of natural gases. Yaghi
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and coworkers31 recently compared the adsorption of various harmful gases by several 
MOF materials to an activated carbon material, Calgon BPL carbon. For each gas, at 
least one o f the MOFs studied exceeded the adsorption potential of BPL carbon. For 
ammonium, the MOFs displayed a 6-105 fold adsorption enhancement. Another group 
showed that the zinc clusters in MOF-5 actually coordinate to ammonia, thus not only 
increasing the adsorption capacity but also serving as a degradation pathway. 32 
Collectively, these results are an indication that MOFs are promising adsorbents for 
harmful gases and with further research may have applications in large-scale industrial 
processes.
In the field of drug adsorption/delivery the size of the pores becomes very important. The 
main drawback of organic porous solids is that their pore sizes are too small to allow for a 
successful incorporation of most organic molecules. With their tunable porosities MOFs 
are able to provide a solution to this problem. Horcajada and coworkers33 showed that the 
rigid mesoporous MOFs, MIL-100 and MIL-101, were able to achieve both a high drug 
loading and a controlled release. MIL-100 and MIL-101 both exhibited high uptake (0.35 
g and 1.4 g o f ibuprofen per gram of MOF, respectively) and 3-6 day release times under 
simulated physiological conditions. Even at these high loadings there was no observed 
loss of crystallinity or decomposition of the frameworks.
Despite the fact that microporous solids are limited to the incorporation of small organic 
molecules, Horcajada et al. 34 also demonstrated the adsorption and delivery capabilities of 
a flexible microporous MOF, MIL-53(Fe). This material adsorbed 0.21 g ibuprofen/g 
MOF and completely released the drug after three weeks. The sustained release profile 
was attributed to the flexibility of the framework, which is able to reversibly open and
30
close its pores upon adsorption of guest species. This property allows MIL-53(Fe) to 
maximize host-guest interactions. More recently, this group investigated the delivery of 
nine drugs from five MIL materials. MIL-100 was able to achieve 25% loading by 
weight of the anticancer drug busulfan, approximately five times higher than the best 
system of polymer nanoparticles (5-6 wt%). Studies on human leukaemia and human 
multiple myeloma cells in culture showed that busulfan-loaded MIL-100 exhibited very 
similar cytotoxic activity to busulfan in its free form. Empty MIL-100 nanoparticles 
exhibited a complete absence of cytotoxicity in the same cell lines. In vitro HIV virus 
replication was significantly inhibited by M IL-100 loaded with the anti-HIV drug AZT- 
TP .35 The MIL family is a unique candidate in the field of drug adsorption/delivery and is 
ready for more extensive in vivo testing.
2.3. Mesoporous Silica Materials
2.3.1. Background
In 1992, researchers at the Mobil Oil Company developed a new class of silica-based 
ordered mesoporous materials (SMMs) known as the M41S phase. At the time, zeolites 
were the most researched and promising porous materials. However, regardless of the 
great amount of work dedicated to them, their pores were restricted to a diameter of about 
15 A, limiting their applications to very small molecules. Unlike zeolites, M41S 
materials could be designed with very large pore sizes, ranging from approximately 2  to 
10 nm .36 Furthermore, they have very large specific surface areas (up to ca. 1500 m2/g), 
high pore volumes (up to ca. 1.5 cm /g) and ordered pore systems with very narrow pore
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size distribution .37 In general, these materials are derived from supramolecular aggregates 
of ionic surfactants in aqueous media, which act as structure-directing agents (SDAs) or 
templates for the silica mesostructure during synthesis.36 The removal of the surfactant 
by solvent extraction or calcination results in the formation of the mesoporous structure. 
The structure of SMMs depends on the surfactant template selected and the synthesis 
conditions (ie. concentration, temperature, co-solvents, additives, etc. ) . 38 Perhaps the 
best-known and most studied member of the M41S materials is the Mobil Crystalline 
Material, MCM-41, which has a hexagonal arrangement of mesopores. Since these first 
mesoporous silicas were discovered progress has been significant, leading to a vast pool 
of SDAs and a variety of synthetic pathways.39 By changing the inorganic precursor, 
organic template, reaction conditions, and synthetic pathway a variety of different 
mesoporous materials are possible.40 For example, using triblock copolymer templates 
under acidic conditions results in the formation of SBA mesoporous silicas. One of the 
better known members of this class is SBA-15, which is characterized by thick pore walls 
(ca. 3 nm) and a two-dimensional channel consisting of a hexagonal array of mesopores 
with diameters between 8  and 30 nm. This material uses the relatively cheap amphiphilic 
triblock copolymer Pluronic 123 as the surfactant in highly acidic media. 37 A common 
feature of all mesoporous silica materials is the homogeneous size of their ordered pore 
networks, which is an especially attractive feature in the field of drug delivery since this 
allows for fine control of drug load and release. In addition, they have sufficient 
mechanical strength, thermal and pH stability, are biocompatible and contain silanol 
surfaces that can be functionalized to allow for an even better control over drug delivery. 
Compared to the M41S family, the SBA family of materials enjoys some advantages.
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Firstly, they have a larger number of silanol groups due to faster condensation, making 
them more suitable materials to which functional groups can be attached. They also have 
larger pores, in addition to the presence of micropores which connect adjacent mesopores 
together within the framework. These can serve to allow for better access of reagents to 
active sites by minimizing the likelihood of blockages within the mesopores.40 All of 
these properties make the SBA family very attractive materials as drug delivery systems.
2.3.2. Synthetic Approaches
Mesoporous silica materials can be synthesized by a number of different methods. The 
majority o f these methods involve the use o f a surfactant in solution to guide the 
formation o f the inorganic mesostructure from the inorganic precursor. Because 
surfactants are composed of both a hydrophilic head group and a hydrophobic tail group 
they will self-assemble into a conformation that minimizes contact between the 
incompatible ends. A significant difference among the various synthesis routes is the 
type of interaction that is made to occur between the surfactant and the inorganic 
precursor, which will greatly influence the type of mesoporous material that is formed.41 
The two most common methods include liquid crystal templating (LCT) and co-operative 
self-assembly (CSA ) . 40
The original M41S family was synthesized by combining appropriate amounts of a silica 
source (e.g. tetraethylorthosilicate (TEOS), Ludox, fumed silica, sodium silicate), an 
alkyltrimethylammonium halide surfactant (e.g. cetyltrimethylammoniumbromide 
(CTAB)), a base (e.g. sodium hydroxide or tetramethlammonium hydroxide (TMAOH)),
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and water. The mixtures were heated at elevated temperatures (>100°C) for 24 to 144 
hours, resulting in the formation of a solid precipitate. After filtering and washing the 
organic-inorganic products with water, they were calcined at about 500°C under a flowing 
gas to bum off the surfactant, yielding the final mesoporous material. In this method, the 
mesoporous structure depends on the hydrocarbon chain length of the surfactant tail 
group, the surfactant concentration, and the influence of organic swelling agents. The 
Mobil Oil researchers postulated that the formation of MCM-41 - the representative 
M41S material - proceeded by either one of two mechanisms. In the first scheme, now 
known as the LCT mechanism, they proposed that the aluminosilicate precursor species 
occupied the space between a pre-existing hexagonal lyotropic liquid crystal (LC) phase 
and deposited on the micellar rods of the LC phase (Figure 2-6). The second scheme, 
now known as the CSA mechanism, was proposed to involve the ordering of the 
surfactants into a hexagonal arrangement, mediated by the inorganic component (Figure 
2-6). Although they were unsure which one of these mechanisms was actually occurring, 
in both, the negative charge of the inorganic component was known to preferentially 
interact with the positively charged ammonium head groups of the surfactant to organize 
and condense into an ordered framework. Subsequent removal of the surfactants, which 
are ordered as a hexagonal array of micellar rods embedded in the silica matrix, are 
removed to produce the open, mesoporous MCM-41 framework.41
It has now been discovered that the second mechanistic pathway was responsible for the 
formation of MCM-41. The first pathway did not take place because the surfactant 
concentrations used were far below the critical micelle concentration (CMC) required for 
hexagonal LC formation. The second pathway was found to proceed by way of a
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cooperative self-assembly of the ammonium surfactant and the silica precursor below the 
CMC. Thus, at low surfactant concentration (as in the case of MCM-41) the CSA 
mechanism proceeds, resulting in the formation of a LC phase. The LCT pathway, on the 
other hand, occurs at such high surfactant concentrations that the silica precursor is not 
even required for the formation of the LC phase .41
composite: inorganic mesoporous materia!
lyotropic Nqud-crystalline phase mesostructured solid/surfactant (shown M CM -41)
(shown 2D hexagonal)
Figure 2-6. Formation of mesoporous materials by structure-directing agents: a) 
true liquid-crystal template mechanism, b) cooperative liquid-crystal template 
mechanism.42
The original synthesis approach that was postulated for M41S materials has been 
extended to at least three new routes to attain different types of structures. In addition to 
the basic route, there now exists the acidic, neutral, and non-ionic routes. Under acidic 
conditions triblock copolymer templates are used to form the SBA silica phases; the 
HMS/MSU family is formed under neutral conditions. A fundamental requirement for
each of these routes is that there is an attractive interaction between the surfactant head
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groups and the silica precursors to ensure inclusion of the SDA without phase separation 
taking place.42 As proposed by Huo et al.,43, 44 a given inorganic precursor (I) and 
surfactant head group (S) require an electrostatic interaction under the synthesis 
conditions. Based on this nomenclature, under basic conditions involving anionic silica 
species and cationic quaternary ammonium surfactants, the charge-interaction pathway 
can be categorized as S+I'. Preparations under acidic conditions occur below the 
isoelectric point (pH ~ 2) of the inorganic silica precursors, whereby the silica species are 
cationic (I+). The same ammonium surfactant S+ can be used as in basic media, but to 
produce an interaction between the two it is necessary to add a mediator halide 
counteranion (X') (S+X 'l+ pathway), which buffers the repulsion between S+ and I+ by 
weak hydrogen-bonding forces. The resulting materials are referred to as acid-prepared 
mesostructures, or APM materials, of which the SBA family is a member. Negatively 
charged surfactants, such as alkyl phosphates could also be used as SDAs under acidic or 
basic conditions. In basic media a mediator metal cation (M+) must be added to ensure an 
interaction through the S‘M+f  pathway. In acidic media a mediator is not required (S'I+ 
pathway). The dominating interactions in these pathways are electrostatic, however when 
nonionic surfactants are used the attractive interactions are mediated through hydrogen 
bonds. The hydrogen-bonding interaction of an alkylamine (S°) head group and 
hydroxylated TEOS (1°) through the S°I° pathway produces materials with thicker walls 
and higher thermal stability than the acidic and basic routes.42 Another hydrogen-bonding 
synthesis route uses the non-ionic surfactant, triblock poly(ethylene oxide)- 
poly(propylene oxide)-poly(ethylene oxide - EO20PO70EO20) (Pluronic 123), wherein the 
PEO units function as the hydrophilic head and alkyl chain and PPO units function as the 
core. The lengths of the head and tail groups can be adjusted, resulting in pores as large
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as 58 A in diameter. The PEO head group (N°) is non-ionic, unlike the amine head group 
(S°) which is uncharged and can be ionized. The result from this non-ionic route (N°I°) is 
materials with greater pore ordering than the neutral route (S°I° ) .40 Each of these 
interactions is illustrated in Figure 2-7.
SBA-15 uses Pluronic 123 as its surfactant, however its synthesis occurs under acidic 
conditions (pH ~ 1). It is thought that the templating of this material occurs through both 
electrostatic and hydrogen-bonding interactions, producing materials with pores as large 
as 30 nm. The orderness of its structure can be improved by decreasing the surfactant 
concentration, allowing for slower assembly of the silica species with surfactant 
molecules. As the size of the micelles increases the corresponding pore size also 
increases, reducing the wall thickness. Pore size can also be increased by either 
increasing the synthesis temperature or time during hydrothermal treatment. SBA-15 also 
has microporosity, which originates from penetration of EO chains in silica walls, 
connecting the different mesoporous cavities. The microporosity can be controlled by 
synthesis temperature, time, and by silica/surfactant ratio .41
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Figure 2-7. Interactions between the inorganic species and the head group of the 
surfactant with consideration of the possible synthetic pathway in acidic, basic, or 
neutral media. Electrostatic: S+I', S+X'I+, S‘M+I', ST+; through hydrogen bonds: 
S0I°/N°I0, S°(XI)0.42
2.3.3. Applications
The unique properties of SMMs have made these materials highly desirable for a number 
of different applications, including catalysis, gas and liquid adsorption, binding metals, 
and drug adsorption/delivery. Their extremely high surface areas and large pore sizes 
allow for high catalytic activity, fixation of large catalytically active complexes and
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enables reactions involving bulky molecules. These materials have seen applications in 
acid/base, oxidative and chiral catalysis. Sulfonic acid derivatives were anchored to 
MCM-41,45,46 MCM-48,45' 46 FSM-1647 and SBA-1548 materials, leading to good yields 
and selectivities in the condensation of phenol and acetone to bisphenol A.45, 46 
Additionally, high activities were reported in the acetalation of acetophenone with 
ethylene glycol,47 and in the dehydration o f 1-butanol to dibutyl ether.48 Friedel-Crafits 
alkylation and epoxidation are also common acid-catalyzed reactions using SMMs.41
The majority o f studies on heterogeneous oxidation catalysts have been devoted to SMMs 
doped with metals, metal complexes, or organometallic compounds.42 For example, 
shortly after the discovery of the M41S materials, two groups simultaneously reported the 
synthesis o f MCM-41 doped with titanium. Catalytically active titanium sites were 
deposited in the mesoporous matrix without significantly affecting surface area or pore 
size. Corma et al.49 prepared Ti-MCM-41, which showed a higher catalytic activity than 
Ti-/? zeolite in the epoxidation of norbomene with tert-butyl hydroperoxide as the 
oxidant. The use of MCM-41 materials as both heterogeneous base and chiral catalysts 
has also shown promising results.42
SMMs also have major potential applications in gas and liquid adsorption, and in binding 
metals as a result of their high porosities. Ioneva et al.50 have shown that the adsorption 
of methane in MCM-41 was possible at 25°C up to 6.9 MPa, with a 75% improvement in 
storage capacity when the pressure was 3.45 MPa. For optimization of methane affinity, 
pores smaller than 2 0  A are ideal. Mesoporous aluminosilica materials are also being 
used to adsorb volatile organic compounds (VOC) at room temperature with great 
capacity. Once saturated, the adsorbents are reactivated with hot air (120-150°C) and the
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recovered VOCs are concentrated 3-10 times.41 These materials have also been purposely 
modified to remove heavy metals from tainted water supplies. For example, Feng et al. 51 
functionalized the surface of a SMM with tris(methoxy)sulfanylpropylsilane molecules 
with thiol terminal groups to adsorb mercury, silver, and lead ions from water. The 
adsorptive power of this material far exceeded that of conventional sorbents. It was also 
reusable, as treatment of the mercury-loaded material with HC1 released the metal, 
yielding the intact functional adsorbent. Furthermore, the work of Liu et al. 52 showed that 
thiolated SBA-15 has a high affinity to mercury cations, and that amino-functionalized 
SBA-15 highly binds copper, zinc, chromium and nickel cations. Thus, these materials 
have promising applications in the removal of heavy metals from wastewaters.
Mesoporous silica materials also have very important applications in the field of drug 
delivery as a result of their highly ordered pores, large pore volumes and high surface 
areas. The well-ordered pore distribution of these materials gives them the ability to 
homogeneously and reproducibly adsorb and release drug molecules. Their high pore 
volumes and high surface areas mean that they can both host vast quantities of drugs in 
their pores and adsorb a large amount of molecules onto their pore walls. Additionally, a 
wide array of functional groups can be grafted to their silanol-containing surfaces, thus 
improving the adsorption and controlled release profiles of biomolecules. Finally, their 
pores are also highly tunable.38
The high density of silanol groups (SiOH) on the surface of SMMs allows for the 
possibility of easy chemical functionalization of the pore walls. Two methods to graft 
chemical groups to the pore walls of SMMs have been described in the literature. The 
first is direct functionalization, in which the selected functional group is present in the
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reaction mixture with a trialkoxysilane during the synthesis process. The second method 
is post-synthesis functionalization, which involves grafting the functional group to the 
mesoporous material after surfactant removal. The type of chemical modification is 
normally selected depending on the nature of the drug molecule to be adsorbed, taking 
into account the desired load and release kinetics. 38
The confinement of a number of different classes of drugs within SMMs has been 
described in the literature, perhaps none more than anti-inflammatory drugs, including 
ibuprofen. The loading of drugs within the mesoporous structures is usually performed 
by soaking the SMM in a highly concentrated drug solution. The loading solvent is 
selected based on the chemical nature of the guest molecule. Usually, the solvent that is 
selected is one in which the drug molecule has a very high solubility. The release process 
is usually performed by placing the impregnated mesoporous material into simulated 
body fluid (SBF) solution, which has ionic concentrations similar to those found in 
human plasma.38
The possibility of using MCM-41 as a DDS was first described in 2001 when Vallet-Regi 
et al.53 performed drug loading and release studies with ibuprofen. Two MCM-41 
matrices with different pore sizes - MCM-41 )6 and MCM-41 n  (2.5 and 1.8 nm, 
respectively) - were synthesized using cationic surfactants with different hydrocarbon 
chain lengths. It has been widely reported that the pore diameter is a limiting factor in 
adsorption of molecules within mesoporous matrices. Ibuprofen, however, has molecular 
dimensions of 1.0 x 0.6 nm, so the pore diameter is not a limiting factor. The adsorption 
o f drug molecules into SMMs is a surface phenomenon governed by the interactions of 
the silanol surface with the functional groups of the guest molecule. The amount of
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ibuprofen adsorbed within the MCM-41 matrices was 34 wt% and 23 wt% for MCM-4116 
and MCM-41 12, respectively. These different drug loadings can be attributed to the 
different surface areas which are 1157 and 1099 m /g, respectively. Thus, the chemical 
interactions between the functional groups o f the drug and the silanol groups of the matrix 
are promoted by higher surface areas. This fact was also illustrated by impregnating 
SBA-15 (602 m /g) with ibuprofen, yielding a smaller drug loading of 15 wt%. Drug 
delivery studies with MCM-41 matrices indicated that the higher the pore size, the faster 
the drug release. The cumulative release o f ibuprofen after 24 h from MCM-41 j6 and 
MCM-4112 was 68% and 55%, respectively. This finding was confirmed by Horcajada et 
al.,54 who demonstrated this trend using several MCM-41 matrices with pore diameters 
ranging in size from 2.5 to 3.6 nm. These results suggest that the delivery rates of SMMs 
can be controlled by choosing an appropriate pore size.
One o f the goals of controlled drug delivery is to achieve a site-specific controlled release 
pattern, which has been accomplished with SMMs by stimuli-responsive controlled 
release. In this approach the DDSs release the encapsulated drug molecules when 
desired, by responding to external stimuli. A change in pH is a stimulus that has been 
used to control the release from several SMMs. Certain tissues of the body are slightly 
more acidic than blood and normal tissue, such as tumour and inflammatory tissue.38 For 
example, Yang et al.55 studied the release o f vancomycin at different pHs (2.0, 4.5 and 
6.5) from a pH-responsive DDS using SBA-15. The pore entrances were modified with 
carboxylic acid; polycations were then adsorbed to the anionic SBA-15 closing the gates 
of the pores with vancomycin inside. Reducing the pH led to the carboxylic species
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(COO') becoming protonated (COOH), resulting in the polycations moving away and 
opening o f the gates for release of the drug.
Possibly one of the most spectacular works in the area of stimuli-sensitive mesoporous 
silica materials was done by Mai et ah , 56,57 who constructed a photochemically controlled 
system using MCM-41. In this strategy the researchers anchored coumarin to the pore 
openings of an MCM-41 preparation in which the SDA was still present. This was done 
to ensure that coumarin reacted only with the silanol groups at the pore openings and the 
outer surface. After removal of the surfactant cholestane derivatives were inserted into 
the pores. Irradiation with UV light (k > 310 nm) led to dimerization of the coumarin, 
resulting in sealing of the pore openings. Diffusion-controlled release of the enclosed 
active compounds was accomplished by cleaving the coumarin dimers with UV light at 
around 250 nm. Other stimuli-sensitive mesoporous silica release systems respond to 
stimuli such as temperature, light and ultrasound, each of which have the ability to 
improve the therapeutic efficacy of standard DDSs.38
2.4. Conclusions
The majority o f research in the domain of metal-organic frameworks has focussed on 
discovering new phases and demonstrating their potential applications in various fields. 
Detailed investigations on the influence of reaction conditions on crystallization are the 
minority. The ability to carefully control drug delivery from these materials requires a 
fundamental understanding of the influence of synthesis conditions on their properties, 
such as particle size, porosity, and surface area. Optimization of the reaction conditions
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also provides an opportunity to minimize energy requirements, which is essential for 
large scale production of MOFs.
Shortcomings of conventional therapy have justified the pursuit of drug delivery systems 
which are capable of improving the therapeutic and pharmacological properties of free 
drugs through a controlled release rate. Polymeric nanoparticles, micelles, liposomes, 
and microporous zeolites have been extensively researched as DDSs, but for the most part 
results have been unsatisfactory. The main drawback of these materials is that they either 
lack a well defined porosity, making a controlled release very difficult, or they have 
porosities that are too small to allow for a high drug loading. With their tunable host- 
guest properties MOFs are able to provide a solution to these problems.
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Recently, inorganic-organic hybrid compounds or metal-organic frameworks (MOFs)
have attracted increasing interest due to their applications in the fields of gas
adsorption/storage, 1-4 catalysis,5' 7 drug storage and delivery, 8 11 electrode materials, 1214
imaging, 1 0 ,15 and magnetism .1618 They result from the assembly of organic linkers and
inorganic species, exclusively by strong covalent and ionocovalent bonds. 19 The success
of these materials is attributed to their remarkable porosity and the easy tunability of their
pore sizes, which can be achieved by changing the organic linker and/or the inorganic
moiety. As a result a huge number of three-dimensional open-framework structures are
possible, with some of the highest surface areas seen for crystalline inorganic solids and
porosities spanning those exhibited by microporous zeolites and mesoporous silica
materials. 19 Moreover, some MOFs have a high structural flexibility and robustness,
enabling them to adapt their porosity to the shape and size of hosted organic molecules.8, 
u
To date the majority of studies on these materials have been devoted to discovering new 
types of MOFs and demonstrating their potential applications in various fields. However, 
detailed investigations about the role of reaction conditions during synthesis and scale up 
have been ignored. Thus far, the majority of MOFs have been synthesized by hydro- or 
solvothermal methods using conventional electric (CE) heating, 19 requiring reaction times 
as long as several days. However, because of the huge potential for industrial 
applications of MOFs, 20 a fundamental understanding of the synthesis of these materials is 
vital if they are to offer viable applications in industry. For MOF production to be scaled 
up to larger industrial processes it is essential to develop new and efficient alternative
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synthesis techniques capable of reducing costs of the final product. To achieve this the 
synthesis times must be reduced and the overall energy efficiency must be improved. To 
this end, alternative techniques such as solvent free methods, 21 electrochemical methods, 20 
ultrasound (UTS) , 22' 24 and microwave (MW) irradiation22,24 27 have been reported.
UTS and MW irradiation are particularly promising alternative techniques due to the 
minimisation of energy and optimization of reaction conditions with these two methods. 
MW irradiation is characterized by accelerated reactions, as a consequence of the intense 
localized heating, reducing reaction times from days and hours by classical heating to 
minutes and seconds.28, 29 Since the magnitude of heating depends on the dielectric 
properties of the molecules, generated energy is supplied to the material directly and 
uniformly. This allows the whole material to be heated rapidly and simultaneously, 
resulting in homogeneous nucléation, fast crystallization, vast reductions in particle size 
and higher yields. 19,28,29 The remarkable effects of UTS energy (20 kHz) are attributed to 
“acoustic cavitation”, the phenomenon involving the formation, growth, and implosive 
collapse of cavitation bubbles generated in a liquid by the ultrasound wave. 28 Accelerated 
reactions result from the violent collapse of thousands of these tiny micrometer-sized 
hotspots, generating extremely high temperatures (> 5000 K), pressure (> 2000 atm), and 
heating and cooling rates (> 1011 K/s) . 28 In addition, UTS irradiation can lead to 
homogeneous nucléation. Despite these impressive capabilities, very little effort has been 
invested into understanding the beneficial effects of MW and UTS irradiation for MOF 
synthesis.
Recently, our group demonstrated a novel hybrid synthesis technique involving initial 
UTS irradiation followed by MW irradiation for rapid synthesis of IRMOF-1.24
50
Compared with IRMOF-1 synthesized by means of CE heating, crystallites synthesized 
using this approach were more cubic shaped, much smaller (size reduction by a 
magnitude o f approximately 10), had a narrower particle size distribution (5-15 pm), and 
had similar high surface areas (-2470 m2/g).24
Additionally, Haque et al. (2010) demonstrated the accelerated syntheses of MIL-53(Fe) 
by UTS and MW irradiation at relatively low temperatures, observing the crystallization 
rate to decrease in the order UTS > MW »  CE. These results and the findings our group 
has made previously suggest that syntheses performed under UTS and MW conditions 
may be very promising for producing MOFs.
In this work we have qualitatively analyzed the crystallization of MIL-53(Fe),30 a 
structurally flexible and non-toxic iron(III) benzenedicarboxylate MOF. The main 
objective of this work was to develop rapid and energy efficient synthesis techniques 
utilizing UTS and MW irradiation. Syntheses were carried out under CE, MW and UTS 
conditions to gain an understanding of the effects of multiple synthesis procedures on the 
product yield and crystallinity. Within each reaction procedure, two-level multi-factorial 
designs were used to study the dependence of the two responses on each factor. The 
structure of MIL-53(Fe) is composed of parallel trans comer-sharing iron(III) octahedral 
chains, each of which are cross-linked by 1,4-benzenedicarboxylate (BDC) anions to 
form a one-dimensional lozenge-shaped pore channel system.11 As mentioned elsewhere, 
MIL-53(Fe) only opens its pores in the presence of guest molecules, therefore, unlike 
other MOFs it does not have a high surface area. MIL-53 has the formula 




The MIL-53(Fe) samples were synthesized with the same batch composition reported by 
Horcajada et al. (2010) from a mixture of ferric chloride hexahydrate (FeCUbFEO, 
Caledon, 97.0-102.0%), 1,4-benzenedicarboxylic acid (FI2BDC, Alfa Aesar, >98%), and 
AV-dimethylformamide (DMF, Caledon, >99.8%) at a molar ratio of 1:1:64. All of the 
chemicals were used as purchased without any further purification. In the first stage of 
the experiment, samples were synthesized by means of an electrical oven (DKN 400, 
Yamato Scientific America, Inc., Santa Clara, CA) to evaluate CE heating. Each reaction 
mixture was prepared by dissolving 1 mmol of FeCE OHiO and 1 mmol of H2BDC in 5 
mL of DMF. The solution was then transferred either to a round bottom flask connected 
to a condenser or to a sealed pressurized glass vessel (Ace Glass, Inc., Vineland, NJ) and 
heated for a specific time (i.e. 2 h or 15 h) at a predetermined temperature (i.e. 100°C or 
150°C) according to the experimental design (Table 3-1). The same batch composition 
and reaction vessels were used for MW irradiation (Discover, CEM Corporation, 
Matthews, NC). The solution was irradiated at a predetermined power (i.e. 150 W or 300 
W), temperature (i.e. 100°C or 150°C) and time (i.e. 10 min or 30 min) (Table 3-2). For 
UTS irradiation, 10 mL of the reaction mixture was added to a vial which was placed in 
the probe of an ultrasonic generator (VCX 500, Sonics & Materials, Inc., Newtown, CT). 
These experiments were performed at a predetermined time (i.e. 7 min, 11 min or 15 min) 
and power (40%, 50% or 60% of maximum power) (Table 3-3), however the temperature 
was not controlled. After completion of each of the reactions and prior to 
characterization the products were cooled to room temperature before centrifugation, then
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washed with DMF and dried. The high and low values used in this study for each of the 
reaction parameters were selected based on results from preliminary experiments.
Table 3-1. Experimental design for MIL-53(Fe) synthesized by CE heating.
S a m p le  c o d e C E  tim e  (h ) C E  tem p erature  O C ) R e a ctio n  v e sse l R e la tiv e  c r y sta llin ity  (% ) Y ie ld  (% )
M I L - 5 3 J 2 1 00 R B  fla sk 9 .9 16 .9
M IL -5 3  J 2 150 R B  fla sk 14 .2 5 1 .8
M IL -5 3  3 15 10 0 R B  fla sk 2 3 .5 5 8 .8
M I L - 5 3 4 15 15 0 R B  fla sk 10 0 56.1
M IL -5 3  5 2 100 P G  v e sse l 3.1 2 5 .9
M IL -5 3 _ 6 2 1 50 PG  v e sse l 6 5 .7 53 .3
M I L - 5 3 J 15 10 0 P G  v e sse l 15.1 6 0 .8
M IL -5 3  8 15 150 PG  v e sse l 8 1 .9 5 7 .3
Table 3-2. Experimental design for MIL-53(Fe) synthesized by MW irradiation.
S a m p le
c o d e
M W  tim e  
(m in )
M W  tem p erature
ç a
M W  p o w e r  
(W )
R eaction
v e sse l
R e la tiv e  
cry sta llin ity  (% ) Y ie ld  (% )
M I L - 5 3 J 10 1 00 1 50 R B  fla sk 10 .2 5.1
M IL -5 3  J O 10 100 3 0 0 R B  fla sk 3 .2 2 .7
M IL -5 3  11 10 150 1 5 0 R B  flask 15 .7 4 1 .2
M IL -5 3  J 2 10 1 50 3 0 0 R B  flask 3 1 .6 4 6 .3
M IL -5 3  13 3 0 1 00 1 5 0 R B  fla sk 14.5 6 .3
M IL -5 3  14 3 0 1 00 3 0 0 R B  flask 10 .9 5 .9
M IL -5 3  15 3 0 1 50 1 5 0 R B  fla sk 3 6 .4 36.1
M IL -5 3  16 3 0 150 3 0 0 R B  fla sk 2 1 .5 5 .5
M IL -5 3  J  7 10 100 1 5 0 PG  v e sse l 5 .5 2 8 .6
M IL -5 3  J  8 10 100 3 0 0 P G  v e sse l 2 .9 2 8 .6
M IL -5 3  19 10 1 50 1 5 0 PG  v e sse l 5 .8 5 4 .5
M IL -5 3  J O 10 150 3 0 0 PG  v e sse l 1 1 . 1 5 0 .6
M IL -5 3  J 1 3 0 100 1 5 0 PG  v e sse l 6 .2 2 9 .8
M IL -53  J 2 3 0 100 3 0 0 PG  v e sse l 3 .8 36.1
M IL -5 3  23 3 0 1 50 1 5 0 PG  v e sse l 55 .1 5 7 .6
M IL -5 3  2 4 3 0 1 50 3 0 0 PG  v e sse l 3 7 .8 5 2 .5
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Table 3-3. Experimental design for MIL-53(Fe) synthesized by UTS irradiation.
S a m p le  c o d e U T S  tim e  (m in ) U T S  a m p litu d e R e la tiv e  c ry sta llin ity  (% ) Y ie ld  (% )
M I L -5 3 _ 7 0 - l 7 4 0 3 2 .9 11 .8
M IL -5 3  7 0 -2 7 4 0 3 9 .7 11 .8
M IL -5 3 _ 7 0 -3 7 4 0 3 1 .9 12.2
M IL -5 3  J 7 1 -1 15 4 0 3 4 .4 18 .4
M IL -5 3 _ 7 1 -2 15 4 0 33.1 25 .1
M IL -5 3  7 1 -3 15 4 0 3 5 .8 2 7 .5
M I L -5 3 _ 7 2 - l 11 5 0 3 2 .6 17.3
M IL -5 3 J 7 2 -2 11 5 0 3 5 .2 17.3
M IL -5 3  7 2 -3 11 5 0 3 6 .8 2 4 .5
M IL -5 3  7 2 -4 11 5 0 3 3 .7 2 5 .3
M I L -5 3 _ 7 3 - l 7 6 0 3 3 .5 12.5
M IL -5 3 _ 7 3 -2 7 6 0 3 8 .6 17.5
M IL -5 3 _ 7 3 -3 7 6 0 4 0 .8 2 0 .4
M IL -5 3  74-1 15 6 0 3 4 .7 2 0 .5
M lL -5 3  7 4 -2 15 6 0 3 5 .7 3 0 .2
M IL -5 3  7 4 -3 15 6 0 3 7 .4 3 0 .2
overnight, yielding the as-synthesized product. Crystal morphologies of the as-
synthesized products were examined with an SEM (S-2600N, Hitachi High Technologies 
America, Inc.). The XRPD data was collected using CuKa irradiation with a Rigaku -  
Miniflex powder diffractometer (Rigaku Americas Corporation, The Woodlands, TX). 
The particles were analyzed over the range 5°<29<30°; data was processed using MDI- 
Jade v 7.5 software. The relative crystallinity of the products was determined by 
comparing the sum of the areas under two diffraction peaks (20 ~ 9.5° and 2 0  ~ 19.0°) 
relative to the most highly crystallized sample prepared.
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3.2.2. Experimental Design
In order to optimize the synthesis of MIL-53(Fe) a statistical approach using a two level, 
multi factorial design was utilized. Design-Expert 7.1.5 software (StatEase, Minneapolis, 
USA) was used to investigate the effect o f each reaction parameter on the crystallinity of 
the synthesized samples. CE, MW and UTS synthesis followed 23, 24 and 22 factorial 
designs, respectively. Additionally, UTS syntheses were performed in triplicate with 
center points incorporated. Detailed indications of the factor levels employed for each of 
the experimental techniques and the responses examined are summarized in Tables 3-1 to 
3-3. Analysis of variance (ANOVA) was used to study which synthesis variables 
significantly influenced MIL-53(Fe) yield and crystallinity. Mathematical models were 
constructed by step-wise backward elimination of the statistically insignificant factorial 
terms and assigned alphabetically coded input factors (Tables 3-4 to 3-9).
Table 3-4. Summary of the ANOVA of the model equation for the product 
crystallinity as a function of MW irradiation.___________________________________
S o u rce Su m  o f  sq u ares D e g r e e s  o f  fr e e d o m  M ean  square F -v a lu e p -v a lu e
M o d e l 2 .41 11 0 .2 2 58 .1 1 0 .0 0 0 7
A -M W  tim e 0.41 1 0.41 1 0 7 .4 8 0 .0 0 0 5
B -M W  tem p eratu re 1.22 1 1.22 3 2 4 .0 3 < 0 .0 0 0 1
C -M W  p o w e r 0 .0 5 3 1 0 .0 5 3 1 3 .9 9 0 .0 2 0 1
D -R e a c t io n  v e s se l 0 .1 6 1 0 .1 6 4 2 .5 4 0 .0 0 2 9
A B 0 .0 4 7 1 0 .0 4 7 1 2 .3 7 0 .0 2 4 5
A C 0 .0 1 8 1 0 .0 1 8 4 .8 1 0 .0 9 3 3
A D 0 .0 3 9 1 0 .0 3 9 1 0 .4 6 0 .0 3 1 8
B C 0.11 1 0.11 2 7 .9 6 0 .0 0 6 1
B D 0 .0 2 9 1 0 .0 2 9 7 .6 6 0 .0 5 0 4
A B C 0 .1 2 1 0 .1 2 3 2 .8 2 0 .0 0 4 6
A B D 0.21 1 0 .21 5 5 .0 4 0 .0 0 1 8
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Table 3-5. Summary of the ANOVA of the model equation for the product 
crystallinity as a function of CE heating.________________________________________
S o u rc e S u m  o f  sq uares D e g r e e s  o f  fr ee d o m M ean  square F -v a lu e p -v a lu e
M o d e l 1 .86 4 0 .4 7 5 0 .3 7 0 .0 0 4 4
A -C E  tim e 0 .5 1 0 .5 5 4 .5 0 .0 0 5 1
B -C E  tem p erature 1.01 1 1.01 1 0 9 .6 5 0 .0 0 1 9
B C 0 .2 1 0 .2 2 2 0 .0 1 8 3
A B C 0 .1 4 1 0 .1 4 15 .33 0 .0 2 9 6
Table 3-6. 
crystallinity
Summary of the ANOVA of the model 
as a function of UTS irradiation.
equation for the product
S o u rc e S u m  o f  sq uares D e g r e e s  o f  fr ee d o m M ea n  sq uare F -v a lu e p -v a lu e
M o d e l 1 1 0 .0 8 3 3 6 .6 9 0 .8 3 0 .5 0 4 3
A -U T S  p o w er 8 3 .7 4 1 8 3 .7 4 1 .90 0 .1 9 5 9
B -U T S  tim e 1 8 .5 0 1 1 8 .5 0 0 .4 2 0 .5 3 0 8
A B 7 .8 4 1 7 .8 4 0 .1 8 0 .6 8 1 6
Table 3-7. Summary of the ANOVA of the model equation for the product yield as a 
function of MW irradiation.
S o u rc e S u m  o f  squares D e g r e e s  o f  freed o m M ea n  sq uare F -v a lu e p -v a lu e
M o d e l 4 7 6 7 .3 8 2 2 3 8 3 .6 9 2 8 .1 9 < 0 .0 0 0 1
B -M W  tem p eratu re 2 5 3 0 .0 9 1 2 5 3 0 .0 9 2 9 .9 2 0.0001
D -R e a c t io n  v e s se l 2 2 3 7 .2 9 1 2 2 3 7 .2 9 2 6 .4 6 0 .0 0 0 2
Table 3-8. Summary of the ANOVA of the model equation for the product yield as a 
function of UTS irradiation.
S o u rc e S u m  o f  sq u ares D e g r e e s  o f  fr ee d o m M ea n  square F -v a lu e p -v a lu e
M o d e l 4 1 1 .5 7 3 1 3 7 .1 9 7 .6 5 0 .0 0 4 9
A -U T S  p o w er 5 0 .0 2 1 5 0 .0 2 2 .7 9 0 .1 2 3 1
B -U T S  tim e 3 5 9 .7 1 1 3 5 9 .7 1 2 0 .0 5 0 .0 0 0 9
A B 1.8 4 1 1 .84 0 .1 0 0 .7 5 4 7
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Table 3-9. Summary of the ANOVA of the model equation for the product yield as a 
function of CE heating._______________________________________________________
S o u rc e S u m  o f  sq uares D e g r e e s  o f  fr ee d o m M ean  square F -v a lu e p -v a lu e
M o d e l 1 8 8 5 .1 8 3 6 2 8 .3 9 5 6 .6 8 0 .0 0 1 0
A -C E  tim e 9 0 5 .2 5 1 9 0 5 .2 5 8 1 .6 6 0 .0 0 0 8
B -C E  tem p erature 3 9 3 .4 0 1 3 9 3 .4 0 3 5 .4 9 0 .0 0 4 0
A B 5 8 6 .5 3 1 5 8 6 .5 3 52 .91 0 .0 0 1 9
3.3 Results and Discussion
MIL-53(Fe) crystals synthesized by means of MW and UTS irradiation were compared 
with those synthesized by CE heating. The XRPD patterns of the most highly crystallized 
as-synthesized samples (Figure 3-1) match well with those reported earlier,8, n ' 22 
confirming that the crystal phase of the products is MIL-53(Fe) as evidenced by their 
monoclinic symmetry (C2/c, No. 15). Figure 3-2 illustrates typical SEM images of 
crystallized MIL-53(Fe) obtained from each of the synthesis methods. Under CE 
conditions a bimodal distribution of particle sizes was obtained, similar to those reported 
earlier.8,22 Two different crystal morphologies can be seen coexisting - large elongated 
triangular prism-shaped crystals ranging in length from 25-250 pm in addition to much 
smaller hexagonal bipyramidal particles, approximately 2.5 pm in diameter (Figure 3- 
2A). Despite the wide size distribution, these phases should be MIL-53(Fe) based on the 
similarity of their XRPD patterns with the other synthesized samples (Figure 3-1) and 
with those reported earlier.8, n ' 22 This non-uniform size distribution can likely be 
explained by simultaneous nucleation and crystal growth as a result of slow heat transfer 
and poor temperature distribution under CE heating.
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Figure 3-1. Typical XRPD patterns of fully crystallized MIL-53(Fe) synthesized by 
a) CE for 18 h at 150°C, b) MW for 30 min at 150°C, and c) UTS for 15 min at 60% 
power.
MIL-53(Fe) crystals synthesized under MW and UTS conditions produced small and 
homogeneous crystals, which is a clear indication of both the crystal phase purity and the 
efficiency of these two synthesis methods. Despite the different scales used to create the 
SEM images, the particles synthesized from both methods can be seen to have 
approximate dimensions of 0.5-1.5 pm and hexagonal bipyramidal morphologies (Figure 
3-2B and Figure 3-2C). This size reduction is typical of crystals synthesized under MW 
or UTS conditions -  a phenomenon which can be attributed to uniform and fast
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nuclealion. Furthermore, small MIF-53(Fe) crystals are especially effective in the Helds
of diffusion, catalysis, and drug adsorption del i\'cry.
Figure 3-2. 'Typical SKM  images of fully crystallized M IF -53(Fe)  synthesized by a) 
C F for 18 h at 150°( (25 pm scale), h) M W  for 30 min at 150°( (5 pm scale), and c) 
F I S  for 15 min at 6 0 %  power (10 pm scale).
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ANOVA was used to determine which synthesis variables significantly influenced MIL- 
53(Fe) yield and crystallinity utilizing models created by Design-Expert 7.1.5. According 
to the data in Tables 3-4 to 3-9, the only model that is not statistically significant (p-value 
> 0.05) is the model predicting product crystallinity from the UTS synthesis method. All 
of the models used for the MW and CE synthesis methods are statistically significant (p- 
value < 0.05). It was found that MW time (F-value = 107.48) and MW temperature (F- 
value = 324.03) strongly influence product crystallinity (Table 3-4). As irradiation time 
and temperature increase, product crystallinity increases. MW power (F-value = 13.99) 
and the reaction vessel (F-value = 42.54) both have a much less significant influence on 
product crystallinity. Likewise, for the CE synthesis method both CE time (F-value = 
54.50) and CE temperature (F-value = 109.65) strongly influence product crystallinity 
(Table 3-5). With the UTS synthesis method, despite performing the experiments in 
triplicate and incorporating center points into the design, the model obtained was not 
significant (F-value = 0.5043) (Table 3-6). Neither the UTS time (F-value = 0.42) nor the 
UTS power (F-value = 1.90) were shown to have a significant influence on product 
crystallinity. The final model equations for each of the methods are shown in Table 3-10.
MW temperature (F-value = 29.92) and the reaction vessel (F-value = 26.46) were the 
factors most strongly influencing product yield (Table 3-7). Much higher yields were 
obtained when the temperature was 150°C and when the pressurized glass vessel was 
used. Under UTS irradiation, the time (F-value = 20.05) had a greater influence on 
product yield than power (F-value = 2.79) (Table 3-8). Longer reaction times generally 
resulted in higher yields. Finally, CE time (F-value = 81.66) more greatly influenced 
product yield than CE temperature (F-value = 35.49) (Table 3-9). Comparing the results
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from each of the three synthesis methods we can see that UTS irradiation resulted in 
much lower yields than CE heating and MW irradiation. This is a surprising result, 
especially considering that higher yields are common when using MW and UTS energies 
instead of conventional solvothermal methods. However, this result can likely be 
explained by the collapse of cavitation bubbles close to or on the walls of the vial, which 
causes a microjet of liquid to be forced to the surface at speeds upwards of 200 m/s. 
Since UTS experiments were performed in an open vial much of the reaction mixture had 
actually escaped as mist, most likely as a result of this phenomenon. The final model 
equations for each of the synthesis methods are shown in Table 3-11.
Table 3-10. Final model equations for product crystallinity from CE heating, MW 
and UTS irradiation.__________________________________________________________
Model equations______________________________________________________________
loglO(RCi) = 1.37 + 0.25A, + 0.36Bi + 0.16B,Ci - 0.13AiB,Ci
loglO(RC2) = 1.32 + 0.16A2 + 0.28B2 - 0.057C2 - 0.10D2 +0.054A2B2 - 0.034A2C2
+ 0.050A2D2 + 0.081B2C2 + 0.043B2D2 - 0.088A2B2C2 + 0.11A2B2D2
RC3 = 87.58 + 2.64A3 - 1.24B3 - 0.81 A3B3_______________________________________
RCi, CE relative crystallinity; Ai, CE time; Bi, CE temperature; Cj, CE reaction vessel; 
RC2, MW relative crystallinity; A2, MW time; B2, MW temperature; C2, MW power; D2, 
MW reaction vessel; RC3, UTS relative crystallinity; A3, UTS power; B3, UTS time.
Table 3-11. Final model equations for product yield from CE heating, MW and UTS 
irradiation._____________________________
Model equations_________________________
Yj = 47.61 + 10.64A] + 7.01B, -  8.56A,B,
Y2 = 30.46 + 12.58B2 + 11.82D2
Y3 = 19.84 + 2,04A3 + 5.48B3 - Q.39A3B3
Y], CE yield; Ai, CE time; Bi, CE temperature; Y2, MW yield; B2, MW temperature; D2, 
MW reaction vessel; Y3, UTS yield; A3, UTS power; B3, UTS time.
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Utilizing the MW synthesis method, we found that in as little as thirty seconds nucléation 
had occurred. The nucléation time was determined by visual observation (when the 
reaction mixture became cloudy). Increasing the time to ten minutes yielded highly 
crystalline materials; the most crystalline materials were obtained after thirty minutes. 
Nucléation was first observed after five minutes under UTS conditions. Since the effects 
of UTS time and UTS power on product crystallinity were shown to be insignificant we 
can conclude that after only seven minutes the products have reached their maximum 
crystallinity for this method. The SEM image of this product (Figure 3-3) shows crystals 
similar to those in Figure 3-2C, confirming the ANOVA results that time and power are 
insignificant. Also, the XRPD spectrum is identical to that obtained after ten minutes of 
MW irradiation at 150°C (Figure 3-4). To the best of the author’s knowledge, these 
reaction times are the shortest to be reported for MIL-53(Fe) synthesis. The onset of 
nucléation under CE heating occurred after twenty minutes, which was forty times longer 
than that observed for MW irradiation. The most crystallized products were obtained 
after fifteen hours (30X and 128X longer than for MW and UTS irradiation, respectively), 
indicating that UTS and MW irradiation are quicker and more efficient alternatives to 
conventional electric heating.
It has generally been accepted that in the majority of cases rate enhancements under 
microwave conditions can be explained by the high reaction temperatures that can rapidly 
be attained in a microwave field.31 This is referred to as the thermal/kinetic effect, but 
“specific microwave effects” caused by dielectric heating must also be considered, and 
these include: 1) the superheating effect, 2) the formation of microscopic hotspots, 3)
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Figure 3-3. SEM image of MIL-53(Fe) synthesized by UTS for 7 min at 40% power.
Figure 3-4. XRPD patterns of MIL-53(Fe) synthesized by a) UTS for 7 min at 40% 
power, and b) MW for 10 min at 150°C.
63
more uniform heating, and 4) selective heating.31 These accelerations (which are still 
currently the subject of considerable debate) cannot be achieved by conventional heating. 
There have also been suggestions of the existence of “non-thermal microwave effects” 
which result from a direct interaction of the electric field with dipolar molecules in the 
reaction medium.31 As already mentioned, accelerated reactions seen under UTS 
irradiation result from “acoustic cavitation” and the implosive collapse of formed 
cavitation bubbles.28
To illustrate the efficiency of MW and UTS syntheses we compared the total 
energy consumption of these two methods to that of CE heating. For this we determined 
the energy required to (1) induce nucleation, and (2) produce the most crystalline 
materials from each method. The microwave operated on a 120V power source at 15 
amps. This was used to calculate the instantaneous power usage, P, in watts (W), as 
shown by Eq. (1):
P = VI (1)
where V is the voltage (V) and I is the current (A). The energy consumption, E, in joules 
(J) was then estimated using Eq. (2):
E = Pt (2)
where P is the constant power (watts) and t is the time (seconds). The microwave 
required approximately 54 kJ and 3,240 kJ of energy for nucleation and maximum 
crystallization, respectively. As determined from ANOVA, UTS time and UTS power 
were not significant factors affecting product crystallinity, therefore, the method requiring 
the least amount of energy will be considered. The ultrasound also operated on a 120V
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power source at 15 amps, which corresponded to 540 kJ and 756 kJ of consumed energy 
for nucleation and maximum crystallization, respectively. Compared to CE heating these 
energy requirements are very low. The oven operated on a 115V power source at 12 
amps, and required approximately 2,500 kJ of energy to reach the temperature set point 
(150°C). With a power rating of 1.2 kW, an energy consumption of 4,320 kJ was 
required to run the oven for one hour at the set point. This corresponded to an energy 
consumption of 3,900 kJ and 67,000 kJ for nucleation and maximum crystallization, 
respectively. Considering these energy requirements, as well as the fact that both MW 
and UTS irradiation produced small, homogeneous crystals compared to the two 
populations of crystals obtained from CE heating, it is evident that these two technologies 
are quicker, more efficient and greener alternatives to conventional synthesis methods.
3.4. Conclusions
MIL-53(Fe), a metal-organic framework (MOF) material, has been synthesized by 
conventional electric (CE) heating, ultrasound (UTS) and microwave (MW) irradiation. 
Crystals were synthesized in as quickly as ten minutes from MW irradiation and in as 
little as seven minutes from UTS synthesis. To the best of the author’s knowledge, these 
are the quickest crystallization times to be reported for MIL-53(Fe). The most crystalline 
materials were synthesized after fifteen hours from CE heating. Crystals produced from 
UTS and MW conditions were small and homogeneous, whereas those produced from CE 
heating had two different morphologies and sizes. The observed size reduction of crystals 
synthesized under UTS and MW conditions can be attributed to fast and uniform
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nucléation. The non-uniform size distribution of particles produced from CE heating is 
likely a result of the method’s inherently slow heat transfer and a poor temperature 
distribution within the reaction mixture. ANOVA was used to create models to determine 
which synthesis variables significantly influenced product yield and crystallinity. UTS 
irradiation resulted in much lower yields than CE heating and MW irradiation, a 
phenomenon that can be explained by microjets of liquid being forced to the surface of 
the reaction mixture during synthesis and escaping into the atmosphere. For both the 
MW irradiation and CE heating methods, time and temperature were shown to have a 
significant influence on product crystallinity. However, for the UTS method neither the 
time nor the power had a significant influence on crystallinity, suggesting that the 
products reached their maximum crystallinity for this method very shortly after 
nucléation. Furthermore, UTS and MW irradiation consume far less energy than CE 
heating, which confirms that these two technologies are quicker, more efficient and 
greener alternatives to conventional synthesis methods.
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Despite our remarkable understanding o f the biological processes responsible for many 
diseases, progress in their treatment has moved slowly. The use of novel drug delivery 
systems (DDSs) can alleviate the shortcomings of conventional therapeutics by allowing 
for a stability of the drug plasmatic levels through a controlled release rate. This 
eliminates the need for high doses, thus increasing the efficiency and decreasing the 
toxicity of conventional drugs. Coupled with the fact that the development of new 
bioactive compounds is a time-consuming, complex and costly process, the interest in 
nanoparticle-based therapeutics has been increasing over the last few years.1 Currently, 
materials being used for delivery are classified as either organic or inorganic systems, 
composed of an active agent incorporated within the nanoparticle carrier. Systems that 
have already been extensively researched include polymeric nanoparticles, micelles, 
liposomes, and microporous zeolites, but are for the most part unsatisfactory. Organic 
systems, including biocompatible dendritic macromolecules or polymers, can be 
encapsulated with a wide array of drugs, however in the absence of a well-defined 
porosity they lack a controlled release.2
A third type of delivery route -  the “hybrid” route -  has recently been proposed.3 Porous 
metal-organic frameworks (MOFs), which fall under this category, exhibit many desirable 
characteristics as drug carriers. They can combine exceptionally high surface areas and 
porosities with the presence of tunable inorganic, organic and functional groups, thus 
achieving both a high drug loading and a controlled release of therapeutic agents to 
targeted areas of the body. Their success is attributed to their remarkable porosity, 
biodegradability, and the tunability of their pore sizes -  a result of the limitless choice of
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organic bridging ligands and metal centers that make up their structures. As a result a 
huge number of three-dimensional open-framework structures are possible, with some of 
the highest surface areas seen for crystalline inorganic solids and porosities spanning 
those exhibited by microporous zeolites and mesoporous silica materials.3 Not only can 
their connectivities be modified to accommodate the physicochemical properties of 
hosted drug molecules, but some MOFs have a high structural flexibility and robustness, 
enabling them to adapt their porosity to the shape and size of organic molecules.4,5
MIL-53 is an example of such an MOF. The hydrated forms MIL-53(A1, Cr) solids 
exhibit a reversible pore opening which involve atomic displacements by 0.52 nm upon 
dehydration, corresponding to an increase in pore volume up to 45%. The dehydrated 
form of MIL-53(Fe), however, remains closed. This material only opens its pores during 
the adsorption of organic molecules, and for this reason exhibits no porosity for nitrogen 
at 77 K.5 A combined XRPD/NMR/modeling study on MIL-53(A1) revealed that 
hydrogen bonding interactions between the hydrogens of the water molecules trapped 
within the channels and the carboxylate groups of the BDC linkers are responsible for 
contraction of the pores.6 This reversible “breathing” effect of certain flexible MOFs has 
been shown to adapt the cell volumes o f their structures by 50-230% without any 
noticeable change to their structural integrities.5
MIL-53(Fe) was previously used as a matrix for the adsorption and in vitro delivery of 
ibuprofen. Horcajada et al. (2008) showed that MIL-53(Fe) adsorbs 0.21 g ibuprofen/g 
MOF and has a very slow and complete delivery of ibuprofen in simulated body fluid at 
37°C over a three week period with an unusual zero-order kinetics drug release. They 
attributed this slow release to the flexibility of the framework, which allows it to
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maximize bonding interactions while still minimizing steric hindrance. Density 
functional theory (DFT) calculations revealed that the most likely interaction between the 
framework and the entrapped ibuprofen molecules involved a strong hydrogen bonding 
between the oxygen of the carboxylic group of ibuprofen and the hydroxyl group of the 
framework located at the surface of the pores. Weaker van der Waals and/or CH -71 
interactions were also found between the hydroxyl and the methyl groups of ibuprofen 
and the organic linker of MIL-53(Fe).5
However, the main drawback of using microporous (pore diameters <2 nm) MOFs such 
as MIL-53(Fe) is that the choice of incorporated species is restricted to relatively small 
drug molecules which are able to fit inside the frameworks, such as ibuprofen. To solve 
this problem, Ferey and co-workers2 demonstrated drug delivery using rigid mesoporous 
(pore diameters between 2 and 50 nm) MOFs, MIL-100 and MIL-101, which proved 
suitable due to their well-defined, ordered porosity. MIL-101 has a Langmuir surface 
area of 5500 m /g, and exhibited a very high drug storage capacity of an unprecedented 
1.4 g of ibuprofen per gram of MOF. The complete release of Ibuprofen was achieved 
under physiological conditions after six days. MIL-101 possesses large mesoporous 
cages (~2.9 and 3.4 nm), and large window openings of 1.2 nm and 1.6 nm for the 
pentagonal and hexagonal windows, respectively. As evidenced by X-ray powder 
diffraction (XRPD), even at these high loadings there was no apparent loss of crystallinity 
or decomposition of the framework structure. Taking into consideration the sustained 
release times and the high drug loadings, the MIL family is a unique candidate for storage 
and controlled release of biologically important molecules.
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Long blood circulation times of MOFs are crucial for in vivo delivery. It is well known 
that particles coated with polyethylene glycol (PEG) chains on their surfaces exhibit 
“stealth” properties, eliminating rapid uptake by the reticuloendothelial system (RES) and 
short blood circulation times. A recent study showed that PEGylated single-walled 
carbon nanotubes (SWNTs) exhibited remarkably long blood circulation times {t\n -  22.1 
h) upon intravenous injection into mice, far exceeding the previous record of 5.4 h.7 It 
has been roughly estimated that a circulation t\n of 12-20 h in mice translates into 
approximately 40-60 h in humans.8 Horcajada et al. (2010) showed that MOFs not 
protected by a PEG coating were rapidly sequestered from the blood by the RES and had 
accumulated in the spleen and liver. Thus, PEGylation of MOFs and SMMs will be an 
important step for prolonging in vivo release profiles.
The aim in this study was to evaluate to what extent reported sustained release times and 
high drug loadings were applicable to a series of three compounds with a high degree of 
physicochemical diversity. The drug loading and release behaviour of acetaminophen, 
stavudine and progesterone encapsulated in either MIL-53(Fe), MIL-101, or a silica- 
based ordered mesoporous material (SMM), SBA-15 were evaluated. SMMs are 
characterized by their homogeneous and ordered pore networks, mechanical strength, 
thermal and pEl stability, biocompatibility and silanol-containing surfaces that can be 
functionalized to allow for a better control over drug delivery.9,10 SBA-15 consists of a 
hexagonally-ordered array of tunable pores which can range in diameter from 5 to 30 nm. 
It also has a high surface area ranging from 600 to 1000 m2/g, and a large pore volume 
ranging from 0.8 to 1.2 cm3/g.n These properties enable drug loadings upwards of 50 
wt%.12 The structure of MIL-53(Fe) is composed of parallel trans comer-sharing iron(III)
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octahedral chains, each of which are cross-linked by 1,4-benzenedicarboxylate (BDC) 
anions to form a one-dimensional lozenge-shaped pore channel system. As previously 
mentioned, MIL-53(Fe) only opens its pores in the presence of guest molecules, 
therefore, unlike MIL-101 it does not have a high surface area. MIL-53 has the formula 
Min(0H)[(02C-C6H4-C02)]-H20 (where M = Al3+, Cr3+ or Fe3+) with pores of free 
diameter close to 1.3 nm.5 MIL-101 is built up from trimers of chromium octahedra, 
which are also cross-linked by BDC, and has the formula Cr3 0 X(H20 )2[(0 2C)-C6H4- 
(C 02)]3-«H20  (where X = F,OH and n is ~25).13
In this study we have attempted to use an incipient wetness impregnation procedure to 
load the materials with the model drugs -  an impregnation procedure which has not yet 
been reported for MOFs. In this procedure a precise amount of highly concentrated 
organic drug solution has been used with great success to fill the mesopores of SMMs.11, 
14, is js a more convenient method than the conventional loading procedure, which 
involves adsorption from an organic solution followed by cumbersome and time- 
consuming equilibration and filtration steps to recover the loaded carrier particles.14 
Furthermore, particles can be loaded with a precisely known quantity of drug molecules 
using the incipient wetness procedure. In contrast, the adsorbed drug quantity in the 
conventional loading procedure is unknown.
As already mentioned, MIL-101 and SBA-15 have been shown to achieve drug loadings 
upwards of 50 wt%. However, MIL-53(Fe) previously achieved a maximum drug 
loading of 20 wt% for ibuprofen.5 Thus, in this study each of the materials was 
impregnated with a targeted drug loading of 20 wt%. The loaded materials were
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evaluated for their release profiles under simulated physiological conditions in phosphate 
buffered saline (PBS).
4.2. Model Drugs
Three drugs were selected based upon their diverse physicochemical properties, in order 
to obtain a test series with a high degree of diversity (Table 4-1). Acetaminophen is an 
analgesic which distributes rapidly and evenly throughout most tissues. Like stavudine, it 
is orally administered, and has a bioavailability ranging from 70 to 90% and a plasma 
half-life ranging from 1.9 to 2.5 hours.16 Stavudine is a nucleoside reverse transcriptase 
inhibitor (NRTI) used for the treatment of human immunodeficiency virus (HIV). It was 
approved for use by the Food and Drug Administration (FDA) in 1994. Seven NRTIs 
have been approved for use, but in general they have limited stability and poor 
bioavailability. As an NRTI, stavudine has a reasonably high bioavailability of about 
80%. However, its half-life in systemic circulation is about 1 to 1.6 hours, which 
necessitates frequent doses, as well as severe dose-dependent side effects.17 Progesterone 
is a steroid hormone belonging to the progestogen class that naturally occurs in both 
males and females. It is administered to individuals with a long-term decline of natural 
levels in the body, as well as to patients with acute situations. Like all steroid hormones 
it is hydrophobic, therefore, when taken orally it has a poor bioavailability and a half-life 
upwards of 50 hours.18 The dimensions of each drug were determined using ChemDraw. 
Acetaminophen (~ 0.82 x 0.49 nm), progesterone (~ 1.12 x 0.58 nm), and stavudine (~
0.85 x 0.58 nm) were all determined to have favourable dimensions for incorporation
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within the pores of each nanomaterial. Acetaminophen was purchased from Sigma- 
Aldrich (St. Louis, MO); progesterone from Calbiochem (La Jolla, CA); stavudine was 
generously donated by Apotex PharmaChem Inc. (Brantford, ON).
Table 4-1. Structural formulas of the model drugs, the wavelengths used for 
quantification and the media used for in  v itr o  drug release experiments.____________
Compound Structural Formula
Wavelength for 
Quantification (nm) Release Medium
Acetaminophen prV 244 PBS
Progesterone 245 PBS + 0.5% SDS




4.3.1. Synthesis of Materials
MIL-53(Fe) was synthesized with the same batch composition reported by Horcajada et 
al. (2010) from a mixture of ferric chloride hexahydrate (FeCNôFLO, Caledon, 97.0- 
102.0%), 1,4-benzenedicarboxylic acid (H2BDC, Alfa Aesar, >98%), and N,N-
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dimethylformamide (DMF, Caledon, >99.8%). All of the chemicals were used as 
purchased without any further purification. The reaction mixture was prepared in a 50 
mL glass beaker by dissolving 5 mmol of FeCL-öFLO and 5 mmol of H2BDC in 25 mL of 
DMF. The beaker was placed in the probe of an ultrasonic generator (VCX 500, Sonics 
& Materials, Inc., Newtown, CT) and subjected to ultrasonic irradiation for 10 min at 
70% of the maximum power; the temperature was not controlled. The as-synthesized 
product was prepared by centrifugation, DMF washing, and overnight drying. Prior to 
drug loading, the as-synthesized sample was subjected to three activation steps. To 
remove DMF from the pores the powder was heated for 24 h at 150°C in an oven (DKN 
400, Yamato Scientific America, Inc., Santa Clara, CA) and cooled down to room 
temperature. To remove traces of DMF, the powder was then stirred in a large volume of 
deionised water and filtered. Finally, the powder was dehydrated in the oven at 150°C for 
24 h to remove water from the pores.
MIL-101 was synthesized hydrothermally according to procedures previously reported2,13 
from a mixture of chromic nitrate nonahydrate (CrINCLL'OFbO, Caledon, >98.0%), 1,4- 
benzenedicarboxylic acid (H2BDC, Alfa Aesar, >98.0%), hydrofluoric acid (HF, EMD 
Chemicals Inc.), and H2O. A solution containing 3 mmol of Cr^CLVOFLO, 3 mmol of 
H2BDC, 0.1 mL of HF (52% in water), and 14.4 mL of H2O was introduced into a 25 mL 
Teflon liner. The mixture was placed in a steel autoclave and heated in a furnace 
(Lindberg Blue M, Thermo Fisher Scientific Inc.) for 10 h at 220°C with a heating ramp 
of 1 h. After a cooling ramp of 3 h back down to room temperature a significant amount 
of free terephthalic acid remained. The reaction mixture was filtered and then washed 
with DMF to eliminate excess terephthalic acid, followed by a wash step with FI2O to
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remove DMF. To remove the remaining terephthalic acid present inside the pores of 
MIL-101, a two-step process involving solvent treatments and a fluoride-anion exchange 
step was performed. The MIL-101 powder was added to 50 mL H2O in a 100 mL round 
bottom flask and refluxed for 5 h, followed by centrifugation and drying in the oven 
overnight at 100°C. Next, the powder was added to 50 mL ethanol in a round bottom 
flask and refluxed for 3 h. Following centrifugation and a wash step with ethanol the 
powder was placed in the oven at 100°C overnight. The powder was then added to an 
aqueous mixture containing 70 mg of ammonium fluoride (NH4F, Alfa Aeasar, >98.0%) 
dissolved in 50 mL of H2O in a 100 mL round bottom flask. The flask was attached to a 
condenser and allowed to reflux for 24 h. The mixture was filtered with 1 pm retention 
filter paper and the powder was washed four times with 50 mL of warm water to remove 
traces of NH4F. Finally, the solid was dried in a vacuum oven (Napco E Series) at 100°C 
overnight under reduced pressure to obtain activated, fine powdered MIL-101.
SBA-15 was synthesized according to procedures described elsewhere. 1 1 14 Four grams of 
triblock copolymer Pluronic 123 (P-123, Sigma-Aldrich) was added to an aqueous HC1 
solution (2 M, 150 mL), and the resulting mixture was stirred until P-123 completely 
dissolved. Once P-123 had dissolved, stirring was allowed to continue while 8 . 6  g of 
tetraethyl orthosilicate (TEOS, Sigma-Aldrich, >99.0%) was added drop-wise during 10 
min. The mixture was then transferred to a 500 mL Teflon bottle and put in the oven at 
100°C for 24 h, followed by filtration and a wash step with H2O. Finally, the silica 
powder was calcined at 500°C for 5 h with a 5 h heating ramp and a 5 h cooling ramp to
remove P-123 from the pores.
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4.3.2. Drug Loading
All model drugs were loaded onto each of the synthesized nanomaterials using an 
incipient wetness impregnation procedure similar to that previously reported,11, 14, 15 in 
order to obtain a drug loading of 20 wt%. A concentrated solution of the drug was 
prepared and added to 50 mg of MIL-53(Fe), or to 100 mg of MIL-101 or SBA-15. 
Concentrated drug solutions were as follows: 50 mg/mL of stavudine in methanol, 30 
mg/mL of acetaminophen in ethanol, and 50 mg/mL of progesterone in dichloromethane. 
The solvents and the concentrations used were selected based on the solubilities of the 
drugs. In a typical loading procedure, the drug solution was added to the powder, which 
was intensively mixed with a spatula until seemingly dry, and subsequently placed in the 
vacuum oven at 70°C under reduced pressure for 24 h to remove any residual solvent. 
The mass of the samples was then recorded to determine the drug loading.
4.3.3. Physicochemical Characterization
In order to study the physical state of the drugs in the porous framework, nitrogen 
adsorption, differential scanning calorimetry (DSC) and XRPD analyses were performed. 
Nitrogen adsorption measurements were recorded with a BET analyzer (Micromeritics 
ASAP 2010). All samples were degassed for 5 h at 40°C before analysis. The 
temperature was kept low to avoid degradation of the drugs. Surface area and total pore 
volume measurements were recorded. DSC analysis was performed with a Mettler 
Toledo DSC 822e (Mississauga, ON). Samples were heated from 25 to 200°C at 2°C/min 
under nitrogen atmosphere at a flow rate of 100 mL/min. The samples were analyzed in
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sealed aluminum crucibles with a small pin hole pressed through the top. The XRPD data 
was collected using CuKa irradiation with a Rigaku -  Miniflex powder diffractometer 
(Rigaku Americas Corporation, The Woodlands, TX). MIL-101 and SBA-15 samples 
were analyzed over the range 2°<29<30°; MIL-53(Fe) samples were analyzed over the 
range 5°<29<30°. Data was processed using MDI-Jade v 7.5 software.
4.3.4. I n  V itro  Drug Release
In order to study release profiles of the drugs, approximately 5 mg of samples loaded with 
either stavudine or acetaminophen were suspended in 15 mL of PBS. Since progesterone 
is poorly soluble in aqueous media, 0.5 wt% of the surfactant sodium dodecyl sulphate 
(SDS) was added to PBS to maintain sink conditions. The mixtures were placed in a 
rotary mixer rotating at a frequency of 100 rpm and suspended in a water bath (37°C) for 
the duration of the experiment. Two millilitre samples were withdrawn with a syringe at 
predetermined time intervals, filtered through a 0.45 pm polytetrafluoroethylene (PTFE) 
membrane filter, and immediately replaced with 2 mL of fresh PBS. Quantification of the 
drug in solution was performed by UV-spectrometry with a Cary 100 UV-Visible 
Spectrophotometer using a quartz cuvette. The wavelengths used for quantification of the 
drugs were selected from the position of the absorption maximum for each of the 
compounds, which was 266 nm for stavudine, 244 nm for acetaminophen, and 245 nm for 
progesterone. Samples were diluted four-fold before their concentrations were 
determined by UV-spectrometry. Their concentrations were calculated by interpolation 
from the calibration curves using linear regression models. The stavudine and
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progesterone calibration curves were linear over the concentration range of 4.6 to 20 
pg/mL and were each constructed by the average of three replicates. The calibration 
curve for acetaminophen was constructed by the average of three replicates over the 
concentration range of 2.2 to 15 pg/mL, and was also linear. All drug release 
experiments were performed in duplicate under sink conditions, and the mean values 
were used to calculate the cumulative drug release after each time interval.
4.4. Results and Discussion
Prior to drug loading, the porosities of MIL-53(Fe), MIL-101 and SBA-15 were evaluated 
by nitrogen adsorption analyses. The porosity, surface area and drug loading 
measurements are presented in Table 4-2. The surface area of each material was 
estimated using the BET model, as shown by Eq. (1):
v ( P o - P )  v '
where P  and Po are the equilibrium and the saturation pressure of adsorbates at the 
temperature of adsorption, v is the adsorbed gas quantity, vm is the monolayer adsorbed 
gas quantity, and c is the BET constant.19 As expected, the surface area of MIL-53(Fe) is 
very low. This is attributed to the fact that MIL-53(Fe) does not have a residual porosity. 
The mesopore volumes and surface areas of MIL-101 and SBA-15 were estimated to be 
0.71 and 1.23 cm /g, and 2212 and 906 m /g, respectively, which are ideal for high drug 
loadings. Drug-loaded MIL-101 and SBA-15 materials were also characterized by 
nitrogen adsorption to investigate the effect on porosity and surface area compared to the
P
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empty carriers. Each of the drug-loaded materials had significantly decreased mesopore 
volumes and surface areas compared to the empty carriers (Table 4-2), evidencing 
successful introduction of the drugs into the pores. Nitrogen adsorption analyses were not 
performed on drug-loaded MIL-53(Fe) samples. As seen in Table 4-2, compared to the 
initially intended theoretical loadings of 20 wt%, the measured loadings were very close. 
The ability to carefully control the drug loading is an obvious advantage of the incipient 
wetness loading procedure over the conventionally used solvent impregnation method. 
The loading time of this method is only dependent on the complete evaporation of the 
solvent, therefore it is much quicker than the solvent method. Additionally, a very small 
volume of solvent is required, so it is also a cost-effective technique.
Table 4-2. BET surface area (Sbet), mesopore volume ( V m e s )  and drug loading 
information of drug-free and drug-loaded MIL-53(Fe), MIL-101 and SBA-15 
samples._________________________________________________________
V m e s  (cm3/g) S b e t  (m2/g) Drug loading (%)
MIL-53(Fe) 0 15 0
MIL-53(Fe)-aceta - - 19.7
MIL-53(Fe)-pro - - 19.6
MIL-53(Fe)-stav - - 20.0
MIL-101 0.71 2213 0
MIL-101-aceta 0.34 1418 19.7
MIL-101-pro 0.28 1290 20.3
MIL-101-stav 0.31 1351 20.0
SBA-15 1.23 906 0
SBA-15-aceta 0.86 420 19.6
SB A- 15-pro - 298 20.2
SBA-15-stav 0.79 402 20.2
DSC is a convenient technique to elucidate the physical state of the drug molecules in the 
drug-loaded samples. It has been shown that the thermodynamic properties of molecules 
confined to porous solids are different from those of the bulk phase, and that below a
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critical pore diameter, crystallization of entrapped molecules is suppressed.20,21 A recent 
study showed that at low temperatures, ibuprofen recrystallized in MCM-41 with a pore 
diameter o f 11.6 nm. However, when the pore diameter was decreased to 3.5 nm it 
existed in a glassy state, since the narrow pore size prevented the molecules from 
arranging themselves into a crystal lattice.22 Crystallization inhibition is typical when 
organic molecules are confined to spaces that are less than 20 times larger than the 
molecular size.23 DSC can detect these phase transitions, allowing us to determine the 
physical nature of the drug-loaded samples. Thus, we can utilize DSC to supplement the 
results from BET analysis, which indicated that the drug molecules had successfully been 
incorporated into each of MIL-101 and SBA-15. Since drug-free and drug-loaded MIL- 
53(Fe) samples do not contain a residual porosity, DSC is an invaluable technique to 
determine if  the drug load had successfully been adsorbed within the microporous MIL- 
53 (Fe) framework.
Figure 4-1 depicts the DSC thermograms o f acetaminophen, progesterone and stavudine 
in their crystalline forms and in the drug-loaded samples. Neither at the bulk melting 
point o f the drugs nor at elevated or depressed temperatures do the drug-loaded MIL-101 
and SBA-15 thermograms show detectable signs of melting. These results can be 
attributed to a complete loss of crystallinity of the confined drug molecules, confirming 
the earlier BET results that the drugs have been successfully incorporated within the 
pores. Drug-loaded MIL-53(Fe) samples, however, do exhibit melting at the 
characteristic melting points of the respective crystalline drugs. This suggests that either 
a partial amount or the entire amount of each drug load deposited onto the surface of the 
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Figure 4-1. DSC thermograms of acetaminophen, progesterone and stavudine in 
their crystallized forms and of drug-loaded MIL-53(Fe), MIL-101 and SBA-15 
materials.
84
much smaller pore diameter and volume than both MIL-101 and SBA-15. In its most 
expanded form, the pore diameter of MIL-53(Fe) is approximately 1.3 nm.5 This is large 
enough to accommodate all three model drugs, which suggests that the pores are 
completely filled with excess molecules deposited onto the surface. The pore volume of 
MIL-53(Fe) is likely too small to accommodate a drug load of 20 wt%.
XRPD analyses were also performed to confirm that the structure of the materials had 
remained unchanged after incorporation of the drug molecules (Figure 4-2). From these 
spectra two conclusions can be made: (1) that the crystal structures of the materials 
remain unchanged, and (2) that the confined drug molecules are in an amorphous state. 
The diffraction peaks of the parent structures are retained in the drug-loaded samples of 
MIL-53(Fe) and MIL-101, indicating that there was no apparent loss of crystallinity or 
decomposition of the framework structure. Although the XRPD spectra of the 
crystallized drug molecules are not shown, we can clearly see that no new diffraction 
peaks were introduced into the drug-loaded samples. This is in agreement with the DSC 
results for MIL-101 and SBA-15, confirming that the confined drugs are in an amorphous 
state.
The in vitro release o f each of the drugs from the drug-loaded materials was investigated 
next (Figure 4-3 to 4-5). There were two distinctive release stages for both MOF delivery 
systems. Initially there was a “burst” release in which a majority of the drug load was 
released very quickly, followed by a slow and sustained diffusion-controlled release 
period. Already after 30 min, the cumulative release of each of the drugs from MIL-101 
had exceeded 90%. The release of progesterone from MIL-53(Fe) in the first 30 min was 
similar to the release from MIL-101, however, the burst release of acetaminophen and of
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Figure 4-2. XRPD patterns of drug-free and drug-loaded MIL-53(Fe), MIL-101 and 
SBA-15 materials.
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stavudine from MIL-53(Fe) was less. This burst release from MIL-53(Fe) suggests that 
the drugs had adsorbed onto the external surface of the particles, which confirms the DSC 
results.
The portion of the loaded drugs that had successfully been incorporated into the pores can 
also be estimated from the burst release amount. Approximately 80% of the total 
acetaminophen amount was rapidly released, suggesting that 20% of the total payload 
was successfully incorporated within the pores. Likewise, approximately 16% and 7% of 
stavudine and progesterone payloads, respectively, were successfully incorporated into 
MIL-53(Fe). Although these results are just an approximation, they seem to suggest that 
the incorporated amount is size-dependent, since the size of the model drugs increases in 
the order: acetaminophen < stavudine < progesterone. The approximations may also be 
an underestimate when considering that a portion of the successfully incorporated drug 
amount may have been released within these first few moments of the experiments. This 
amount, however, is likely very small due to the strong host-guest interactions present 
within the flexible MIL-53(Fe) microporous framework.
Indeed, these strong interactions are evidenced by the second release stage for each of the 
drug-loaded MIL-53(Fe) materials. A complete delivery of stavudine and progesterone 
occurred after five days; acetaminophen was completely released after six days (Figure 4- 
3). The release process is governed mainly by diffusion from the pores and by drug- 
matrix interactions. By virtue of its flexibility, MIL-53(Fe) is able to adopt a 
configuration in which the interactions between guest molecules and the framework are 
optimized. This adaptability might explain the long release times, which could result 
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Figure 4-3. Cumulative release of acetaminophen (■), progesterone ( A ) ,  and 
stavudine (o) from MIL-53(Fe) in PBS at 37°C. The depicted results are mean 








2 3 4 5
Time (days)
Figure 4-4. Cumulative release of acetaminophen (■), progesterone ( A ) ,  and 











Figure 4-5. Cumulative release of acetaminophen (■), progesterone ( A ) ,  and 
stavudine (o) from SBA-15 in PBS + 0.5% SDS at 37°C. The depicted results are 
mean values (n  =  2).
Ibuprofen was previously reported to completely release from MIL-53(Fe) after a period 
of three weeks.5 However, utilizing a three day solvent impregnation method this group 
successfully incorporated 20 wt% of ibuprofen within the pores, which is higher than the 
loadings achieved in this study. This higher drug loading is likely the reason for a longer 
release profile. Successive experiments will need to be conducted with MIL-53(Fe) to 
determine if multiple incipient wetness impregnation steps can increase the incorporated 
drug amount.
The burst release from MIL-101 requires a different explanation, since BET, DSC and 
XRPD analyses indicated that each drug-loaded sample had successfully incorporated the 
entire payload within the pores. The quick release likely results from a rapid dissolution, 
and subsequent quick diffusion from the relatively large mesopores. It is likely that the
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drug fraction not directly contacting the surface of the mesopores immediately dissolved 
upon immersion within the release medium. Due to the large diameter of the mesopores, 
any resistance to diffusion out of the pores is likely very weak, resulting in rapid 
diffusion.
Similarly to the drug-loaded MIL-53(Fe) materials, the second release stage was 
prolonged, and governed by diffusion from the pores and by host-guest interactions. The 
complete release of stavudine from MIL-101 occurred after five days, which is 
comparable to the complete release of ibuprofen after six days from MIL-101 that was 
previously reported.2 Progesterone was completely released after three days; 
acetaminophen after two days (Figure 4-4). These release kinetics are quicker than the 
MIL-53(Fe) kinetics, which is expected since the release is dependent on diffusion from 
the pores and host-guest interactions, which are likely much higher in drug-loaded MIL- 
53(Fe) materials. This clearly shows an influence of the flexibility of MIL-53(Fe) on the 
time of release.
These results suggest that very long therapies are possible using flexible MOFs for drug 
delivery. Stavudine suffers from a short half-life in systemic circulation, which 
necessitates frequent doses, causing severe dose-dependent side effects. The benefits of 
controlled delivery for this drug, as well as for a wide range of other pharmaceuticals with 
either low bioavailabilities or short circulating half-lives would include stable blood 
concentrations, a minimization of toxicity and adverse side effects, as well as increased 
patient compliance.24
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All SBA-15 formulations released their payloads very quickly. Acetaminophen and 
stavudine were completely released from SBA-15 in less than an hour; 100% release of 
progesterone occurred after four hours (Figure 4-5). Rapid release from MIL-101 and 
SBA-15 materials results from fast dissolution of the confined molecules, followed by 
rapid diffusion from the mesopores into the release medium. Since sink conditions were 
installed for each of the release experiments, the slightly slower release of progesterone is 
a result of a slower diffusion out of the pores. Therefore, the dissolution of progesterone 
into the release medium cannot be considered a rate-limiting process. This indicates that 
the pore diameter may have been small enough to cause diffusive resistance during the 
release of relatively bulky progesterone molecules.
Several studies have reported that mesoporous silica materials can enhance the 
dissolution rates of incorporated drugs.11,14,25 Van Speybroeck et al. (2009) observed that 
the in vitro release profiles of ten poorly soluble drugs from SBA-15 was faster than the 
dissolution of their respective crystalline counterparts. All formulations, except for one, 
released 80% of drug within the first 5 min of experiment, which is similar to our results 
for SBA-15. This enhanced dissolution has been attributed to the complete loss of 
crystallization of the adsorbed drug fraction, as it is well known that the high free energy 
associated with noncondensed states can greatly improve dissolution rates.26 As 
evidenced by DSC and XRPD, each of the incorporated drugs existed in an amorphous 
state within the SBA-15 mesopores. An enhanced dissolution can partially account for 
the quick release kinetics, however, the effect was likely minimal since all release 
experiments were performed under sink conditions. The quick release is more likely
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attributed to the large diameter of the mesopores and by adsorption competition between 
the drug molecules and water in favour of the latter.14
4.5. Conclusions
Using an incipient wetness impregnation method, three model drugs (acetaminophen, 
progesterone, and stavudine) were successfully loaded into MlL-53(Fe), MIL-101 and 
SBA-15. The MIL-101 and SBA-15 adsorbed drug fractions were found to be 
noncrystalline, as evidenced by DSC and XRPD analyses. DSC analysis indicated that 
each of the drug-loaded MIL-53(Fe) samples contained a portion of the entire drug load 
that had deposited onto the outer surface of the particles that had recrystallized. This is 
attributed to the smaller pore volume of MIL-5 3 (Fe), which proved to be too small to 
accommodate a drug loading of 20 wt% for each of the model compounds. Nevertheless, 
the portion of the drug load that had successfully been incorporated within the MIL- 
53(Fe) framework was slowly released in as long as six days for acetaminophen in a 
diffusion-controlled process. Owing to the larger pore diameters and weaker host-guest 
interactions, MIL-101 release kinetics were somewhat quicker. However, release times 
were still prolonged, as evidenced by the complete release of stavudine which occurred 
after five days. Prolonging the release of stavudine and other pharmaceuticals using 
MOFs would alleviate many of the drawbacks encountered with conventional 
therapeutics. The release of the model drugs from SBA-15 was much quicker than from 
both MOF materials. In this study, acetaminophen and stavudine were completely 
released from SBA-15 in less than an hour; 100% release of progesterone occurred after
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four hours. The molecules can easily diffuse into the bulk medium due to the size of the 
pores of the mesostructured silica. SBA-15 has proven to be very useful at enhancing the 
dissolution rates of poorly soluble drugs. Thus, SBA-15 is best-suited for improving 
drug-dissolution, which is ideal for progesterone since it is very poorly soluble due to its 
hydrophobic structure.
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The first stage of the experimental work was to optimize the synthesis conditions of MIL- 
53(Fe) to produce small and homogeneous crystals while minimizing energy 
consumption. Syntheses were carried out under CE, MW, and UTS conditions to gain an 
understanding of the effect of each synthesis procedure on the product yield and 
crystallinity. Within each reaction procedure, two-level multi-factorial designs were used 
to study the dependence of the two responses on each factor. The research carried on to 
investigate the drug loading and release behaviour of acetaminophen, stavudine, and 
progesterone impregnated in either MIL-53(Fe), MIL-101, or SBA-15. The model drugs 
were introduced into the pores of the materials by an incipient wetness impregnation 
procedure, after which drug delivery studies were performed under simulated 
physiological conditions.
5.1.2. Rapid and efficient crystallization of MIL-53(Fe) by ultrasound and 
microwave irradiation
Synthesis of MIL-53(Fe) under UTS and MW conditions is quicker, more efficient and a 
greener alternative to CE heating. MIL-53(Fe) was synthesized in ten minutes from MW 
irradiation and in seven minutes from UTS irradiation, which, to the author’s knowledge, 
are the quickest reported crystallization times for MIL-53(Fe). The observed size 
reduction and homogeneity of MIL-53(Fe) crystals synthesized under UTS and MW 
conditions is attributed to fast and uniform nucléation, and is a clear indication of the
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crystal phase purity and the efficiency of these two synthesis methods. Small MIL-53(Fe) 
crystals are especially effective in the fields of diffusion, catalysis, and drug 
adsorption/delivery. Time and temperature were the most significant factors influencing 
product crystallinity for both MW irradiation and CE heating. For the UTS method, 
neither time nor power significantly influenced product crystallinity, suggesting that the 
products reached their maximum crystallinity shortly after nucléation.
5.1.3. MIL-53(Fe), MIL-101, and SBA-15 as potential platforms for drug delivery
Measured drug loadings of the nanomaterials were very close to the intended theoretical 
loadings of 20 wt%. The advantage of the incipient wetness impregnation procedure over 
conventional solvent loading methods is that it requires only a very small volume of 
solvent, it is a much less time-consuming process, and it allows for the loaded drug 
amount to be carefully controlled. Drug-loaded MIL-53(Fe) materials completely 
released stavudine and progesterone after five days; acetaminophen was completely 
released after six days. The flexibility of the MIL-53(Fe) framework might explain the 
long release times, which could result from maximized host-guest interactions. Very long 
therapies are possible using flexible MOFs for drug delivery. MIL-101 completely 
released stavudine after five days; progesterone was completely released after three days; 
acetaminophen after two days. Larger pore diameters and slightly weaker host-guest 
interactions are responsible for moderately quicker release kinetics. Stavudine and 
acetaminophen were completely released from SBA-15 in less than an hour; complete 
release of progesterone occurred after four hours. Rapid release results from fast
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dissolution of the confined molecules, followed by rapid diffusion from the mesopores 
into the release medium.
5.2. Recommendations
1. Optimization of MlL-53(Fe) synthesis reaction conditions using nontoxic 
solvents.
Synthesis of MIL-53(Fe) was conducted using a class 2 solvent (Health Canada), DMF, 
due to its excellent solubilizing properties. The use of a nontoxic solvent to synthesize 
MIL-53(Fe) may be desirable for potential large-scale production processes, however it 
must be considered that small changes in solvent polarity and pH can lead to poorer 
quality crystals, reduced yields, or the formation of entirely new phases.1 MIL-53(Fe) has 
previously been synthesized in water,2 however the crystals were very large, therefore 
they are not suitable for drug delivery. Thus, optimization experiments using either water 
and/or ethanol are recommended. Alcohols are often used to synthesize MOFs; the use of 
ethanol to synthesize MlL-53(Fe) may be promising since it easily dissolves H2BDC.
2. Control of the burst release from MIL-53(Fe) and MIL-101.
The burst release of each of the three model drugs (acetaminophen, progesterone, and
stavudine) from MIL-53(Fe) and MIL-101 must be controlled. Drug-loaded MIL-53(Fe) 
particles should be washed to remove drug molecules deposited onto the outer surface of 
the particles. Following this, the drug content remaining inside the pores needs to be 
determined before in vitro drug release studies are conducted. Additionally, successive 
incipient wetness impregnation steps should be conducted to determine if the 
incorporated drug amount within MIL-53(Fe) micropores can be increased. The organic
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linker of MIL-53(Fe) and MIL-101 can also be functionalized to attempt to increase the 
affinity of the drug molecules to the framework for extended release profiles. However, 
this may decrease the porosity of each framework, decreasing the drug loading amount.
3. Cellular uptake studies of DDSs.
Finally, comprehensive cellular uptake studies should also be conducted. The size and 
surface charge of the DDSs will need to be carefully controlled to achieve high uptake 
efficiencies.
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Characterization studies of model drugs
Figure A -l. XRPD pattern of acetaminophen.
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Figure A-2. XRPD pattern of progesterone.
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Figure A-6. Nitrogen adsorption isotherm of SBA-15 at 77 K, degassed at 323 K
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Appendix B
Calibration curves and UV absorbance data used to determine cumulative release 
(%) of the model drugs from MIL-53(Fe), MIL-101, and SBA-15
Figure B -l. Calibration curve of acetaminophen (X, = 244 nm) in PBS solution. The 
depicted results are mean values (n  =  3) .
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Figure B-2. Calibration curve of progesterone (X, = 245 nm) in PBS + 0.5% SDS 
solution. The depicted results are mean values (n  = 5).
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Figure B-3. Calibration curve of stavudine (X = 266 nm) in PBS solution. The 
depicted results are mean values (n = 3).
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Table B -l. UV absorbance measurements and sample data used to determine the
cumulative release (%) of acetaminophen from MIL-53(Fe) after each time interval
(trial #1).____________________________________________________________________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
(M S/mL)
A m o u n t
R e leased
(Mg)
C u m u la tiv e
R e lease
(Mg)
A m o u n t 
R e m a in in g  in 
S o lu tio n  (g g )
C u m u la tiv e
R e le a se  (% )
5 m in 0 .6 5 6 9 8 .03 3 2 .1 3 0 482 4 8 2 4 1 8 4 5 .8
15 m in 0.9421 11.42 4 5 .6 7 2 7 .8 7 2 6 7 749 594 71 .2
3 0  m in 0.9051 10.98 43 .91 3 9 .5 8 65 814 571 7 7 .4
4 5  m in 0 .7 8 7 4 9 .5 8 3 8 .3 2 3 8 .0 6 4 818 4 9 8 77 .8
6 0  m in 0 .6 7 9 7 8 .3 0 33.21 33.21 0 818 4 3 2 77 .8
9 0  m in 0 .5891 7 .23 2 8 .9 2 2 8 .7 8 2 820 3 7 6 7 7 .9
2  h 0 .5 0 7 9 6 .2 7 2 5 .0 6 2 5 .0 6 0 820 3 2 6 7 7 .9
3 h 0 .4 4 4 5 5.51 2 2 .0 5 2 1 .7 2 5 825 2 8 7 78 .4
4  h 0 .3 8 6 7 4 .8 3 19.31 19.11 3 828 251 78 .7
1 d 0 .4 3 3 6 5 .38 2 1 .5 4 16.74 72 9 0 0 2 8 0 8 5 .6
2 d 0 .4 4 4 8 5 .52 2 2 .0 7 18.67 51 951 2 8 7 9 0 .4
3 d 0 .4 0 2 4 5.01 2 0 .0 6 19 .12 14 965 261 9 1 .7
4  d 0 .4051 5 .05 2 0 .1 8 17.38 4 2 1007 2 6 2 9 5 .7
5 d 0 .3821 4 .7 7 19 .09 17.49 2 4 1031 2 4 8 9 8 .0
6 d 0 .3 3 2 6 4 .1 9 16.75 16.55 3 1034 2 1 8 98 .3
7 d 0 .2 8 5 6 3 .6 3 14.51 14.51 0 1034 189 98 .3
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Table B-2. UV absorbance measurements and sample data used to determine the
cumulative release (%) of acetaminophen from MIL-53(Fe) after each time interval
(trial #2).____________________________________________________________________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e le a sed
(Mg)
C u m u la tiv e
R e lease
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 0 .9393 11.38 4 5 .5 3 0 683 683 592 6 6 .6
15 m in 0 .8 7 8 8 10.67 4 2 .6 6 3 9 .4 6 4 8 731 555 71 .2
3 0  m in 0 .7 9 9 7 9 .73 38.91 3 6 .9 7 29 760 506 74.1
4 5  m in 0 .7 0 3 0 8 .58 3 4 .3 2 3 3 .7 2 9 769 4 4 6 7 5 .0
6 0  m in 0 .6 2 4 8 7 .65 30.61 2 9 .7 4 13 782 3 9 8 76 .2
9 0  m in 0 .5 3 8 8 6 .63 2 6 .5 3 2 6 .5 3 0 782 345 76 .2
2 h 0 .4 6 9 9 5.81 2 3 .2 6 2 2 .9 9 4 786 302 76 .6
3 h 0 .4 3 5 4 5.41 2 1 .6 2 2 0 .1 6 22 808 281 78 .8
4  h 0 .4 1 4 0 5 .15 20.61 18 .74 2 8 836 268 81.5
1 d 0 .4 3 9 0 5 .45 2 1 .7 9 17.86 59 895 283 8 7 .2
2 d 0 .4 2 1 3 5 .2 4 2 0 .9 5 18.89 31 9 2 6 2 7 2 9 0 .3
3 d 0 .4 0 7 4 5 .07 2 0 .2 9 18.16 3 2 9 5 8 2 6 4 9 3 .4
4  d 0 .3 6 7 2 4 .6 0 18.39 17.59 12 9 7 0 2 3 9 94 .5
5 d 0 .3 3 6 6 4 .2 3 16.94 15.94 15 985 2 2 0 9 6 .0
6  d 0 .2 9 4 7 3 .7 4 14.94 14.68 4 989 194 9 6 .4
7 d 0 .2 5 2 7 3 .2 4 12.95 12.95 0 9 8 9 168 9 6 .4
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Table B-3. UV absorbance measurements and sample data used to determine the
cumulative release (%) of progesterone from MIL-53(Fe) after each time interval
(trial #1)._______ _______________ _______ ________ _____ ___ i_________ __________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C one .
(p g /m L )
A m o u n t
R e leased
(Mg)
C u m u la tiv e
R e lease
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 0 .8 1 5 5 13.85 5 5 .4 0 0 831 831 720 7 9 .4
15 m in 0 .7 8 6 7 13 .39 5 3 .5 5 48 .01 83 914 6 9 6 87.3
3 0  m in 0 .7 1 6 2 12.25 49 .01 46.41 3 9 953 6 3 7 9 1 .0
4 5  m in 0 .6 3 8 6 11.00 44 .01 4 2 .4 7 23 9 7 6 572 9 3 .2
6 0  m in 0 .5 5 6 8 9 .6 8 3 8 .7 4 3 8 .1 4 9 985 504 94.1
9 0  m in 0 .4 7 6 6 8 .3 9 3 3 .5 7 3 3 .5 7 0 985 4 3 6 94.1
2 h 0 .4 1 1 3 7 .3 4 2 9 .3 6 2 9 .1 0 4 9 8 9 3 8 2 94 .5
3 h 0 .3 5 1 5 6 .3 8 2 5 .5 2 2 5 .4 5 1 9 9 0 3 3 2 9 4 .6
4  h 0 .2 9 8 7 5 .53 22.11 22 .11 0 9 9 0 2 8 7 9 4 .6
1 d 0 .2 6 4 3 4 .9 7 19 .90 19 .16 11 1001 2 5 9 9 5 .6
2 d 0 .2 3 2 4 4 .4 6 17.85 17.25 9 1010 2 3 2 96 .5
3 d 0 .2 1 0 0 4 .1 0 16 .40 15.47 14 1024 213 9 7 .8
4  d 0 .1 9 3 6 3 .8 4 15.35 14.21 17 1041 199 9 9 .4
5 d 0 .1 6 6 0 3 .3 9 13.57 13 .30 4 1045 176 9 9 .8
6 d 0 .1 3 7 9 2 .9 4 11 .76 11 .76 0 1045 153 9 9 .8
7 d 0 .1 1 3 6 2 .5 5 10 .19 10 .19 0 1045 132 9 9 .8
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Table B-4. UV absorbance measurements and sample data used to determine the
cumulative release (%) of progesterone from MIL-53(Fe) after each time interval
(trial #2)._______ _______________________ ________ ________ ____________________
T im e A b s o rb a n c e
C o n e .
(H g/m L )
S am p le
C o n e .
(p g /m L )
S ta r lin g
C o n e .
(p g /m L )
A m o u n t
R e leased
(Mg)
C u m u la tiv e
R e le ase
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 0 .8 8 3 8 14.95 5 9 .8 0 0 897 897 777 86.5
15 m in 0 .8 0 2 4 13.64 54 .56 51 .83 41 938 709 90 .5
3 0  m in 0 .7081 12.12 4 8 .4 9 4 7 .2 9 18 956 6 3 0 9 2 .2
4 5  m in 0 .6 1 4 0 10.61 4 2 .4 2 4 2 .0 2 6 9 6 2 551 9 2 .8
6 0  m in 0 .5 2 6 2 9 .1 9 3 6 .7 6 3 6 .7 6 0 9 6 2 4 7 8 9 2 .8
9 0  m in 0 .4 5 3 2 8 .0 2 3 2 .0 6 3 1 .8 6 3 965 4 1 7 93.1
2 h 0 .3 9 0 9 7.01 2 8 .0 5 2 7 .7 9 4 9 6 9 365 9 3 .4
3 h 0 .3 3 2 9 6 .0 8 24.31 24.31 0 9 6 9 3 1 6 9 3 .4
4  h 0 .2 8 2 5 5 .2 7 2 1 .0 7 2 1 .0 7 0 9 6 9 2 7 4 9 3 .4
1 d 0 .2 6 3 8 4 .9 7 19.86 18.26 24 993 258 9 5 .8
2 d 0 .2371 4 .5 4 18.15 17.21 14 1007 2 3 6 97.1
3 d 0 .2 0 8 9 4 .0 8 16.33 15.73 9 1016 2 1 2 9 8 .0
4  d 0 .1 8 2 3 3 .6 5 14.62 14.15 7 1023 190 9 8 .6
5 d 0 .1 5 6 2 3 .2 3 12.94 12.67 4 1027 168 9 9 .0
6 d 0 .1 2 9 4 2 .8 0 11.21 11.21 0 1027 146 9 9 .0
7 d 0 .1 0 6 2 2 .4 3 9 .7 2 9 .7 2 0 1027 126 9 9 .0
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Table B-5. UV absorbance measurements and sample data used to determine the
cumulative release (%) of stavudine from MIL-53(Fe) after each time interval (trial
#1)._____________________________________________________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S a m p le
C o n e .
(pg /m L >
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e le a sed
(Mg)
C u m u la tiv e
R e lease
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e  
R e le ase  (% )
5 m in 0 .6 0 4 9 11.18 4 4 .7 3 0 671 671 582 63.3
15 m in 0 .7 1 6 7 12.26 4 9 .0 4 3 8 .7 7 154 825 637 77.8
3 0  m in 0 .6 2 6 6 10.81 4 3 .2 3 4 2 .5 0 11 836 562 78 .9
4 5  m in 0 .5 6 0 9 9 .75 3 9 .0 0 3 7 .4 7 23 859 507 81 .0
6 0  m in 0 .4 9 7 7 8.73 3 4 .9 3 3 3 .8 0 17 876 4 5 4 82 .6
9 0  m in 0 .4 3 4 7 7 .72 3 0 .8 8 3 0 .2 8 9 885 401 83.5
2 h 0 .3 7 1 9 6.71 2 6 .8 3 2 6 .7 6 1 8 8 6 3 4 9 83 .6
3 h 0 .3 2 3 6 5 .93 2 3 .7 2 2 3 .2 5 7 893 308 84 .2
4  h 0 .2 7 7 6 5 .1 9 2 0 .7 5 2 0 .5 5 3 8 9 6 2 7 0 84.5
1 d 0 .2 7 5 0 5 .15 2 0 .5 9 17 .99 39 935 2 6 8 88 .2
2 d 0 .2 5 6 2 4 .8 4 19 .37 17 .84 23 9 5 8 252 9 0 .4
3 d 0 .2 6 0 6 4.91 19 .66 16 .79 43 1001 2 5 6 9 4 .4
4  d 0 .2 4 1 6 4.61 18 .44 17 .04 21 1022 2 4 0 9 6 .4
5 d 0 .2 1 2 8 4 .1 4 16 .58 15 .98 9 1031 2 1 6 97 .3
6  d 0 .1 7 9 5 3.61 14.43 14.37 1 1032 188 9 7 .4
7 d 0 .1 4 9 6 3 .1 3 12.51 12.51 0 1032 163 9 7 .4
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Table B-6. UV absorbance measurements and sample data used to determine the
cumulative release (%) of progesterone from MIL-53(Fe) after each time interval
(trial #2)._______ _______________ ________________ ________ ____________________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C one .
(p g /m L )
A m o u n t
R e leased
(Mg)
C u m u la tiv e
R e lease
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 0 .7 1 9 0 13.25 5 3 .0 0 0 795 795 6 8 9 7 5 .6
] 5 m in 0 .7 1 3 0 12 .20 4 8 .8 0 4 5 .9 3 43 838 634 79 .7
3 0  m in 0.6451 11.11 4 4 .4 3 4 2 .2 9 32 870 578 8 2 .7
4 5  m in 0 .5 6 9 7 9 .8 9 3 9 .5 7 3 8 .5 0 16 886 514 84 .2
6 0  m in 0 .4 9 3 0 8 .6 6 3 4 .6 3 3 4 .2 9 5 891 4 5 0 8 4 .7
9 0  m in 0 .4 2 5 4 7 .5 7 3 0 .2 8 30.01 4 895 394 85.1
2 h 0.3721 6.71 2 6 .8 4 2 6 .2 4 9 9 0 4 349 8 5 .9
3 h 0 .3 1 9 6 5 .87 2 3 .4 6 2 3 .2 6 3 9 0 7 305 86 .2
4  h 0 .2 7 9 4 5 .2 2 2 0 .8 7 2 0 .33 8 915 271 8 7 .0
1 d 0 .2 7 8 6 5 .2 0 2 0 .8 2 18.08 41 9 5 6 271 9 0 .9
2 d 0 .2 6 8 6 5 .0 4 2 0 .1 8 18.04 3 2 9 8 8 2 6 2 9 3 .9
3 d 0 .2 4 6 5 4 .6 9 18.75 17.49 19 1007 2 4 4 9 5 .7
4  d 0.2191 4 .2 5 16.98 16.25 11 1018 221 9 6 .8
5 d 0 .1 9 9 5 3 .9 3 15 .72 14.72 15 1033 2 0 4 9 8 .2
6 d 0 .1 6 6 9 3.41 13.62 13.62 0 1033 177 9 8 .2
7 d 0 .1 3 8 7 2 .9 5 11.81 11.81 0 1033 153 9 8 .2
Table B-7. UV absorbance measurements and sample data used to determine the 
cumulative release (%) of acetaminophen from MIL-101 after each time interval 
(trial #1)._______ ______________ ________ ________ ________ ____________________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(M g/m L)
S ta r tin g
C one .
(p g /m L )
A m o u n t
R e le a sed
(Mg)
C u m u la tiv e
R e le a se
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 1 .0459 12.65 5 0 .5 9 0 759 759 658 69 .3
15 m in 1 .1648 1 4 .06 56 .23 4 3 .8 7 185 9 4 4 731 86.1
3 0  m in 1 .0278 12.43 4 9 .7 3 4 8 .7 3 15 9 5 9 647 87.5
4 5  m in 0 .8 7 7 4 10.65 4 2 .6 0 4 3 .1 3 0 9 5 9 562 87.5
6 0  m in 0 .7 8 6 0 9 .5 6 3 8 .2 6 3 7 .4 7 12 971 4 9 7 8 8 .6
9 0  m in 0 .6 8 7 2 8 .3 9 3 3 .5 7 3 3 .1 3 7 9 7 8 4 3 7 89 .2
2  h 0 .6 1 0 7 7 .4 9 2 9 .9 4 2 9 .1 3 12 9 9 0 3 8 9 90 .3
3 h 0 .5 4 3 0 6 .6 8 2 6 .7 3 2 5 .9 3 12 1002 3 4 8 9 1 .4
4  h 0 .4 8 0 8 5 .9 4 2 3 .7 8 2 3 .2 0 9 1011 3 0 9 9 2 .2
1 d 0 .5201 6.41 2 5 .6 4 2 0 .6 0 76 1087 313 9 9 .2
2 d 0 .4 4 6 6 5 .54 2 2 .1 5 2 2 .0 4 2 1089 271 9 9 .4
3 d 0 .3 6 4 4 4 .5 6 18.25 19.08 0 1089 235 9 9 .4
4  d 0 .3 1 0 8 3 .93 15.71 16.55 0 1089 2 0 4 9 9 .4
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Table B-8. UV absorbance measurements and sample data used to determine the
cumulative release (%) of acetaminophen from MIL-101 after each time interval
(trial #2)._______ _______________ _______ ________ ________ _______
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C one .
(p g /m L )
A m o u n t
R e leased
(MS)
C u m u la tiv e
R e lease
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 1 .1182 13.51 5 4 .0 2 - 810 8 1 0 702 79.1
15 m in 1 .1020 13.31 5 3 .2 5 4 6 .8 0 97 907 693 88 .6
3 0  m in 0.9921 12.01 4 8 .0 4 4 6 .2 0 2 8 935 625 91 .3
4 5  m in 0 .8 5 8 0 10 .42 4 1 .6 7 4 1 .6 7 0 935 542 91 .3
6 0  m in 0 .7531 9 .1 7 3 6 .7 0 3 6 .1 3 9 9 4 4 478 9 2 .2
9 0  m in 0 .6 5 1 0 7 .9 6 3 1 .8 5 3 1 .8 7 0 9 4 4 398 9 2 .2
2 h 0 .5 7 9 5 7 .12 2 8 .4 6 2 6 .5 3 13 9 5 7 3 7 0 93 .5
3 h 0 .5 1 8 3 6 .3 9 2 5 .5 6 2 4 .6 7 13 9 7 0 3 3 2 9 4 .7
4  h 0 .4 7 3 5 5 .8 6 2 3 .4 3 2 2 .1 3 2 0 9 9 0 305 9 6 .7
1 d 0 .4 4 4 6 5.51 2 2 .0 6 2 0 .3 3 2 6 1016 2 8 7 9 9 .2
2 d 0 .3 7 9 9 4 .7 5 18 .99 19.13 0 1016 2 4 9 9 9 .2
Table B-9. UV absorbance measurements and sample data used to determine the 
cumulative release (%) of progesterone from MIL-101 after each time interval (trial 
# 1). _________________ ________ _______________________________ ___________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S a m p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e le a sed
(Mg)
C u m u la tiv e
R e lease
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 0 .6 6 1 3 11.37 4 5 .4 7 0 682 682 591 6 3 .4
15 m in 0 .8 1 5 6 13.85 5 5 .4 0 3 9 .4 0 2 4 0 9 2 2 720 85 .7
3 0  m in 0 .7 5 7 8 12 .92 5 1 .6 8 4 8 .0 2 55 9 7 7 672 9 0 .8
4 5  m in 0 .6591 11.33 4 5 .3 3 4 4 .7 9 8 985 589 91.5
6 0  m in 0 .5 7 6 6 10 .00 4 0 .0 2 3 9 .2 8 11 9 9 6 520 9 2 .6
9 0  m in 0 .4 9 8 0 8 .7 4 3 4 .9 5 3 4 .6 8 4 1000 4 5 4 9 2 .9
2  h 0 .4391 7 .7 9 3 1 .1 5 3 0 .2 9 13 1013 405 94.1
3 h 0 .3 9 7 3 7 .1 2 2 8 .4 7 2 7 .0 0 22 1035 3 7 0 9 6 .2
4  h 0 .3 5 1 9 6 .3 8 2 5 .5 4 2 4 .6 7 13 1048 3 3 2 9 7 .4
1 d 0 .2 9 9 0 5 .53 2 2 .1 3 2 2 .1 3 0 1048 2 8 8 9 7 .4
2 d 0 .2 5 3 2 4 .8 0 19 .18 19 .18 0 1048 2 4 9 9 7 .4
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Table B-10. UV absorbance measurements and sample data used to determine the
cumulative release (%) of progesterone from MIL-101 after each time interval (trial
#2)._______________________________________________________________ __________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(fig /m L )
S ta rtin g
C o n e .
(p g /m L )
A m o u n t
R e leased
(Mg)
C u m u la tiv e
R e lease
(u s )
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e  
R e le a se  (% )
5 m in 0 .5 1 3 3 8 .9 8 3 5 .9 3 0 539 539 4 6 7 0
15 m in 0 .7 3 4 9 12.55 50.21 3 1 .1 4 2 8 6 825 653 54.1
3 0  m in 0 .7 5 6 2 12 .90 5 1 .5 8 43.51 121 9 4 6 671 82 .7
4 5  m in 0 .6505 11.19 4 4 .7 7 4 4 .7 0 9 4 7 582 9 4 .9
6 0  m in 0 .5 5 7 8 9 .7 0 3 8 .8 0 3 8 .8 0 0 9 4 7 504 9 5 .0
9 0  m in 0 .4 7 8 5 8 .42 3 3 .6 9 33 .63 1 948 4 3 8 9 5 .0
2  h 0 .4 1 7 0 7 .43 2 9 .7 3 2 9 .2 0 8 9 5 6 3 8 7 95.1
3 h 0 .3 5 6 5 6 .4 6 2 5 .8 4 2 5 .7 7 1 957 3 3 6 9 5 .9
4  h 0 .3 1 1 3 5 .73 2 2 .9 3 2 2 .3 9 8 965 298 9 6 .0
1 d 0 .2701 5 .0 7 2 0 .2 7 19.87 6 971 263 9 6 .8
2 d 0 .2 4 1 6 4.61 18.43 17.57 13 9 8 4 2 4 0 9 7 .4
3 d 0 .2 0 6 5 4 .0 4 16 .18 15.98 3 9 8 7 2 1 0 9 8 .7
4  d 0 .1 7 3 0 3 .5 0 14.02 14.02 0 9 8 7 182 9 9 .0
Table B -ll. UV absorbance measurements and sample data used to determine the 
cumulative release (%) of stavudine from MIL-101 after each time interval (trial 
#1)._____________________________________________________ ____________________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e le a sed
(Mg)
C u m u la tiv e
R e le a se
(Mg)
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 0 .6 9 6 8 12.85 5 1 .3 9 0 771 771 668 8 8 .0
15 m in 0 .5 8 0 0 10.73 4 2 .9 3 4 4 .5 3 0 771 582 8 8 .0
3 0  m in 0 .5 3 7 7 9 .9 7 3 9 .8 6 3 8 .8 0 16 787 518 8 9 .8
4 5  m in 0 .4 3 7 4 8 .15 3 2 .6 0 3 4 .5 3 0 787 453 8 9 .8
6 0  m in 0 .4 0 1 7 7 .5 0 30 .01 3 0 .2 0 0 787 393 8 9 .8
9 0  m in 0 .3 6 1 2 6 .7 7 2 7 .0 7 2 6 .2 0 13 800 352 9 1 .3
2 h 0 .2 7 9 8 5 .2 9 2 1 .1 7 2 3 .4 7 0 800 3 1 0 9 1 .3
3 h 0 .2 7 8 7 5 .27 2 1 .0 9 2 0 .6 7 6 806 2 7 4 9 2 .0
4  h 0 .2 5 3 0 4.81 19.23 18.27 14 820 2 5 0 9 3 .6
1 d 0 .2 2 0 0 4.21 16 .84 16.67 3 823 2 1 9 9 3 .9
2 d 0.2001 3 .85 15 .40 14.60 12 835 2 0 0 95 .3
3 d 0 .1 8 8 4 3 .6 4 14.55 13.33 18 853 189 9 7 .4
4  d 0 .1 6 2 4 3 .1 7 12.67 12.60 1 854 165 9 7 .5
5 d 0 .1 4 2 0 2 .8 0 11 .19 11.00 3 857 146 9 7 .8
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Table B-12. UV absorbance measurements and sample data used to determine the
cumulative release (%) of stavudine from MIL-101 after each time interval (trial
#2). _________ _______________________ ________ ________ __________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
{p g /m L )
A m o u n t
R e leased
( m s)
C u m u la tiv e
R e lease
(Mg)
A m o u n t
R e m a in in g
(Mg>
C u m u la tiv e
R e lease  (% )
5 m in 0 .5 8 2 8 10.78 4 3 .1 3 0 647 6 4 7 561 71 .7
15 m in 0 .6 3 1 0 10.88 4 3 .5 2 3 7 .3 8 92 739 566 81 .9
3 0  m in 0 .5 6 6 8 9 .8 5 3 9 .3 8 37.71 25 764 512 84 .7
45  m in 0 .4 8 9 4 8 .6 0 3 4 .4 0 3 4 .1 3 4 768 4 4 7 85.1
6 0  m in 0 .4 1 8 2 7 .45 29.81 29 .81 0 768 3 8 8 85.1
9 0  m in 0 .3 6 4 8 6 .5 9 2 6 .3 7 2 5 .8 4 8 776 343 86 .0
2 h 0 .3 1 0 2 5.71 2 2 .8 5 2 2 .8 5 0 776 2 9 7 86 .0
3 h 0 .2701 5 .07 2 0 .2 7 19.81 7 783 2 6 4 86 .8
4  h 0 .2 4 5 8 4 .6 8 18 .70 17.57 17 800 243 88 .7
1 d 0 .2 4 3 3 4 .6 4 18 .54 16.21 35 835 241 9 2 .6
2 d 0 .2 2 6 6 4 .3 7 17.47 16.07 21 856 2 2 7 9 4 .9
3 d 0 .2 0 3 9 4 .0 0 16.01 15.14 13 869 2 0 8 96 .3
4  d 0 .1 7 3 9 3 .5 2 14 .07 13.87 3 872 183 9 6 .7
5 d 0 .1 4 4 8 3 .05 12 .20 12.20 0 872 159 9 6 .7
Table B-13. UV absorbance measurements and sample data used to determine the 
cumulative release (%) of acetaminophen from SBA-15 after each time interval 
(trial #1)._______ _______________ _______ ________ ________ ___________________
T im e A b s o rb a n c e
C o n e .
(H g/m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e le a sed
(Mg)
C u m u la tiv e
R e lease
( u s )
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e  
R e lease  (% )
5 m in 0 .9 6 0 4 11.63 4 6 .5 3 0 698 698 605 66 .3
15 m in 1 .3087 15.77 6 3 .0 6 4 0 .3 3 341 1039 8 2 0 9 8 .7
3 0  m in 1 .1554 13.95 5 5 .7 9 5 4 .65 17 1056 725 100.3
4 5  m in 0 .9 9 8 7 12 .09 4 8 .3 5 4 8 .3 5 0 1056 629 100.3
6 0  m in 0 .8 6 2 8 10 .48 4 1 .9 0 4 1 .9 0 0 1056 545 100.3
9 0  m in 0 .7 4 5 0 9 .0 8 3 6 .3 2 3 6 .3 2 0 1056 4 7 2 100.3
2  h 0 .6 4 3 0 7 .8 7 3 1 .4 7 3 1 .4 7 0 1056 4 0 9 100.3
3 h 0 .5 5 4 6 6 .8 2 2 7 .2 8 2 7 .2 8 0 1056 355 100.3
4  h 0 .4 7 7 9 5.91 2 3 .6 4 2 3 .6 4 0 1056 3 0 7 100.3
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Table B-14. UV absorbance measurements and sample data used to determine the
cumulative release (%) of acetaminophen from SBA-15 after each time interval
(trial #2)._______ _______________ _______ ________ ________ ____________________
T im e A b s o rb a n c e
C o n e .
(M g/mL)
S am p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e le a sed
(Mg)
C u m u la tiv e
R e lease
<gg)
A m o u n t
R e m a in in g
(gg>
C u m u la tiv e
R e le a se  {%)
5 m in 1 .0967 13.25 5 3 .0 0 0 795 795 689 76 .8
15 m in 1 .2470 15.03 6 0 .1 3 4 5 .9 3 213 1008 782 9 7 .4
3 0  m in 1 .0949 13.23 5 2 .9 2 52 .12 12 1020 688 9 8 .6
4 5  m in 0 .9 5 6 0 11.58 4 6 .3 3 4 5 .8 6 7 1027 602 9 9 .2
6 0  m in 0 .8 2 5 9 10.04 4 0 .1 5 4 0 .1 5 0 1027 522 9 9 .2
9 0  m in 0 .7 1 3 0 8 .7 0 3 4 .8 0 3 4 .8 0 0 1027 4 5 2 9 9 .2
2  h 0 .6 1 5 3 7 .5 4 3 0 .1 6 3 0 .1 6 0 1027 392 9 9 .2
3 h 0 .5 3 0 5 6 .5 3 2 6 .1 4 2 6 .1 4 0 1027 340 9 9 .2
4  h 0 .4571 5 .6 6 2 2 .6 5 2 2 .6 5 0 1027 2 9 4 9 9 .2
Table B-15. UV absorbance measurements and sample data used to determine the 
cumulative release (%) of progesterone from SBA-15 after each time interval (trial 
# 1). ___________ _________ ____________________________ __________ ________________________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C one .
(p g /m L )
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e leased
(g g )
C u m u la tiv e
R e le a se
(WÜ
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 0 .3591 6 .5 0 2 6 .0 0 0 3 9 0 3 9 0 338 3 6 .6
15 m in 0 .7 0 8 9 12.13 4 8 .5 3 2 2 .5 3 3 9 0 780 631 73.1
3 0  m in 0 .7 9 5 0 13.52 5 4 .0 8 4 2 .0 7 180 9 6 0 703 9 0 .0
4 5  m in 0 .6 7 1 4 11.53 4 6 .1 2 4 6 .8 7 0 9 6 0 611 9 0 .0
6 0  m in 0 .6 1 9 2 10 .69 4 2 .7 6 4 0 .7 3 3 0 9 9 0 555 9 2 .8
9 0  m in 0 .5 4 1 6 9 .4 4 3 7 .7 6 3 7 .0 0 11 1001 4 9 0 9 3 .8
2  h 0 .4 8 8 7 8 .5 9 3 4 .3 5 3 2 .6 7 25 1026 4 4 6 9 6 .2
3 h 0 .4223 7 .5 2 3 0 .0 7 2 9 .7 3 5 1031 391 9 6 .6
4 h 0 .3 6 1 6 6 .5 4 2 6 .1 6 2 6 .0 7 1 1032 3 4 0 9 6 .7
1 d 0 .2 9 8 0 5 .5 2 2 2 .0 7 2 2 .6 7 0 1032 2 9 6 9 6 .7
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Table B-16. UV absorbance measurements and sample data used to determine the
cumulative release (%) of progesterone from SBA-15 after each time interval (trial
#2). _________ _______________ _______ ________ ________ ____________________
T im e A b s o rb a n c e
C o n e .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e leased
(Mg)
C u m u la tiv e
R e le ase
(Mg)
A m o u n t
R e m a in in g
( u s )
C u m u la tiv e
R e le a se  (% )
5 m in 0 .4 5 5 3 8.05 3 2 .2 0 0 483 483 4 1 9 4 4 .5
15 m in 0 .8 1 4 0 13.83 55.31 27 .91 411 894 719 8 2 .4
3 0  m in 0 .7 9 6 8 13.55 5 4 .2 0 4 7 .9 3 9 4 988 705 91.1
4 5  m in 0 .7 2 1 9 12.34 4 9 .3 7 4 6 .9 7 3 6 1024 642 9 4 .4
6 0  m in 0 .6 4 5 6 11.11 4 4 .4 6 4 2 .7 9 25 1049 578 9 6 .7
9 0  m in 0 .5 6 4 9 9 .8 2 3 9 .2 6 3 8 .5 3 11 1060 510 9 7 .7
2  h 0 .4 9 0 9 8 .62 3 4 .4 9 3 4 .0 3 7 1067 4 4 8 98 .3
3 h 0 .4 2 0 5 7 .4 9 2 9 .9 6 2 9 .8 9 1068 3 8 9 9 8 .4
4  h 0 .3 5 8 5 6 .4 9 2 5 .9 7 2 5 .9 7 0 1068 3 3 8 9 8 .4
1 d 0 .3 0 4 8 5 .63 2 2 .5 0 2 2 .5 0 0 1068 293 9 8 .4
Table B-17. UV absorbance measurements and san 
cumulative release (%) of stavudine from SBA-15 aft
iple data used to det 
ter each time interva
;ermine the 
(trial #1).
T im e A b so rb a n c e
C one .
(p g /m L )
S am p le
C o n e .
(p g /m L )
S ta r tin g
C o n e .
(p g /m L )
A m o u n t
R e leased
(Kg)
C u m u la tiv e
R e lease
(Mg)
A m o u n t 
R e m a in in g  in 
S o lu tio n  (p g )
C u m u la tiv e
R e le a se  (% )
5 m in 0 .4 7 5 2 8 .83 3 5 .3 3 0 530 530 4 5 9 4 9 .8
15 m in 0 .8 7 0 7 14.74 5 8 .9 6 3 0 .6 2 425 955 766 8 9 .7
3 0  m in 0 .7 9 7 3 13.56 54 .23 5 1 .0 9 4 7 1002 705 94.1
4 5  m in 0 .6 8 5 0 11.75 4 7 .0 0 4 7 .0 0 0 1002 611 94.1
6 0  m in 0 .5 8 7 8 10.18 4 0 .7 3 4 0 .7 3 0 1002 530 94.1
9 0  m in 0 .5 0 3 4 8 .83 3 5 .3 0 3 5 .3 0 0 1002 4 5 9 94.1
2 h 0 .4 3 0 4 7 .65 3 0 .5 9 3 0 .5 9 0 1002 398 94.1
3 h 0 .3 6 7 0 6 .63 26 .51 2 6 .51 0 1002 345 94.1
4  h 0 .3 1 2 2 5 .74 2 2 .9 8 2 2 .9 8 0 1002 2 9 9 94.1
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Table B-18. UV absorbance measurements and sample data used to determine the
cumulative release (%) of stavudine from SBA-15 aftter each time interva (trial #2).
T im e A b so rb an ce
C o n e .
(M g/m L)
S am p le
C o n e .
(M g/m L)
S ta r lin g
C o n e .
(M g/m L)
A m o u n t
R e leased
(MR)
C u m u la tiv e
R e lease
(^ g )
A m o u n t
R e m a in in g
(Mg)
C u m u la tiv e
R e le a se  (% )
5 m in 0 .5313 9 .8 5 3 9 .4 0 0 591 591 512 54 .6
15 m in 0 .9088 15.35 61.41 3 4 .1 5 4 0 9 1000 798 92 .3
3 0  m in 0 .8335 14 .14 5 6 .5 6 5 3 .2 2 50 1050 735 9 7 .0
45 m in 0 .7 2 3 6 12 .37 4 9 .4 8 4 9 .0 2 7 1057 643 9 7 .6
60  m in 0 .6 2 1 2 10 .72 4 2 .8 9 4 2 .8 9 0 1057 558 9 7 .6
90  m in 0 .5 3 2 4 9 .2 9 3 7 .1 7 3 7 .1 7 0 1057 483 9 7 .6
2 h 0 .4555 8 .05 32.21 32.21 0 1057 4 1 9 9 7 .6
3 h 0 .3 8 8 8 6 .9 8 2 7 .9 2 2 7 .9 2 0 1057 363 9 7 .6
4  h 0 .3310 6 .05 2 4 .1 9 2 4 .1 9 0 1057 315 9 7 .6
